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ABSTRACT

Synthetic materials embedded with stimuli-responsive cleavable bonds have been
extensively utilized for the development of site-targeted drug delivery system and
selective imaging reporters. We developed stimuli-sensitive materials with two different
redox switches including trimethyl-locked quinone propionic acid and nitrobenzyl
moieties. Novel redox-sensitive polymeric nanoparticles and micelles were prepared from
a synthesized monomer containing trimethyl-locked quinone propionic acid as a redox
trigger. A hydrophobic cancer drug, paclitaxel, was incorporated into the redoxresponsive polymeric nanoparticles and micelles prepared from the synthesize polymers.
The effect of redox stress on the nanoparticles and micelles was evaluated with a
chemical reductant, sodium dithionite demonstrating that the significant amount of
paclitaxel was released at a simulated redox-state compared to the control. Cell viability
studies revealed that the polymer was non-toxic and the nanoparticles and micelles could
release paclitaxel to suppress breast cancer cell growth. In addition to the drug delivery
system, a p-nitrobenzyl moiety redox trigger was utilized to develop a novel NIR
fluorescent

probe,

p-nitrobenzyl

3,7-bis(dimethylamino)-10H-phenothiazine-10-

carboxylate for the selective imaging and therapy. Conjugating methylene blue with a pnitrobenzyl moiety enables it to quench electron transfer within the molecules. Moreover
ii

the redox trigger caged probe released active methylene blue by nitroreductase-mediated
1,6-elimination resulting exhibition of strong fluorescence (λmax = 680 nm) with the
excitation at 580 nm. The fluorescence emission was also induced by incubation with live
Escherichia coli bacteria. It was demonstrated that the NIR fluorescent probe generated
singlet oxygen after nitroreductase mediated reduction with a laser irradiation at a
wavelength of 634 nm. The redox trigger caged NIR fluorescent probe would be a
suitable imaging sensor to detect bacteria expressing NTR. In addition, the probe also
possesses potential as an MB prodrug which can be applied for the treatment of various
diseases.
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CHAPTER 1
INTRODUCTION
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The aim of this chapter is to provide an insight into the principles behind the
experimental work reported in this dissertation work. First, an introduction to redox
microenvironment and its associated therapeutic opportunities are given, followed by an
overview of redox triggers applied in the design of redox-responsive delivery system.
The chapter concludes by discussing the advantages redox triggers may offer for targeted
drug delivery systems and selective imaging.
Numerous modern drug delivery strategies seek to maximize the therapeutic
potential of drug molecules at the targeted site and to minimize their side effects in
healthy tissues. Potent anticancer therapeutic agents are generally non-selective to normal
cells, leading to severe cytotoxic complication. Targeted drug delivery systems have been
considered as a promising tool to alleviate such toxicity by distributing the cytotoxic
drugs favorably to tumor sites in the body. For selective drug release in the desired site,
stimuli-responsive polymer-based drug delivery systems have been extensively
explored.1 The bioresponsive delivery systems can undergo conformational and/or
physiochemical property changes and release incorporated drugs in response to the
signals stemming from tumor microenvironments such as low pH2, altered oxidationreduction (redox)3, over-expressed enzymes4 and hyperthermia5. In addition to the
targeted drug delivery system approach for the improvement of therapeutic effect,
selective imaging is also pivotal in achieving accurate disease diagnostics and monitoring
2

therapeutic efficacy and processes. The key to an effective imaging strategy is the use of
reporters that can be detected by various imaging devices. Radiotracers, magnetic probes
and fluorescent agents are widely utilized reporters in research settings.6 Among these,
the use of fluorophores is a promising tool for imaging due to advantages including high
resolution, sensitivity and non-invasiveness.7 However, fluorescent probes with emission
at short wavelengths have the limitation of poor tissue penetration owing to interference
with the background auto-fluorescence from biomolecules.8 To overcome such
limitations, fluorophores with emission in the far red and near-infrared (NIR), in the
range of 600-1000 nm, have been investigated because absorption and autofluorescence
are minimal in those wavelength ranges.9 Various approaches have been made to achieve
selective imaging sensitivity of NIR fluorophores.10 Latent fluorescent probes, by virtue
of being switchable/activatable, can be turned on by undergoing a user-designated
chemical reaction triggered by specific stimuli. These activatable molecular probes
improve the achievable target-to-background ratios. Such activatable probes are generally
dependent on targeting groups such as a small molecules, peptides, and proteins.11
Recently the altered redox status between intracellular and extracellular compartment has
gained attention as an emerging strategy to achieve the targeted drug release and selective
imaging.

1.1. Cellular redox microenvironments and therapeutic opportunities
Cellular metabolism and integrity are maintained by balancing the redox state of
all the cellular components to maintain optimal overall functions. Redox homeostasis is
3

therefore vital to all organisms and is closely involved with redox reactions in which
electrons and/or hydrogen atoms are transferred between donor and acceptor molecules.
In response to redox imbalance, however, the redox gradient between intracellular and
extracellular compartments becomes notably greater, which induces new metabolic
pathways to restore optimal overall function. During these intracellular redox-regulatory
processes, various redox agents are expressed12 and can serve as an important indicator of
the redox status.13 In conjunction with the disease-related cellular redox changes, the
redox gradient between intracellular and extracellular spaces has inspired the paradigm of
redox-responsive biomaterials intended for intracellular drug delivery.14

1.2. Redox triggers
Synthetic and macromolecular chemistry provides access to a wide range of
redox-susceptible materials. Considering a number of redox agents expressed during the
intracellular redox-regulatory pathways, it is crucial to select an appropriate redox trigger
which responds specifically and selectively at the desired site of action for the responsive
material architecture. Selected redox-triggers including disulfide, quinone and nitro
compounds are discussed with their applications in biomedical materials as follows.

1.2.1. Disulfide bond and glutathione
A disulfide bond, formed through the oxidation of two thiols is a valuable
functional group in a variety of chemical and biological agents exhibiting potent
4

reactivity or biological activities. This bond has already been found in proteins, oxidized
glutathione, and even in numerous natural products including some drugs (e.g.,
mitomycin disulfides, leinamycin, etc.).15 In mildly oxidizing environments, the disulfide
bond is relatively stable. However, disulfide bonds are rarely found inside cells, since
disulfide bond can be easily cleaved by glutathione (GSH) which is the most abundant
thiol-containing small molecule. In the human body, intracellular GSH concentration
reaches 10 mM in cellular fluids while plasma and other body fluids drops the GSH
concentration to 20 µM.16 In addition, tumor cells have also shown an elevated

Figure 1.1. The reduction of a disulfide substrate to free thiols. (i) Formation of a
glutathione-substrate mixed disulfide and substrate free thiol; (ii) release of the second
substrate free thiol and formation of GSSG; (iii) reduction of GSSG to GSH by GSSG
reductase.
intracellular reduced glutathione concentration, a ~7-fold increase in vitro, in comparison
with that of normal cells.17 Therefore, intracellular drug delivery has heavily taken

5

Figure 1. 2. GSH-transporter-targeted prodrug conjugates 1 and 2.
advantage of GSH-mediated thiol exchange. GSH can react with disulfide bonds through
its cysteine-based thiol, which reduces the disulfide substrates to their corresponding free
thiols and oxidizing glutathione to glutathione disulfide (Figure 1.1.). Because of this
unique property of disulfide bond, it has been extensively applied for cancer research as
an efficient redox trigger.

The disulfide chemistry applied for a
variety

of

materials

including

prodrugs18,

dendrimer19, liposome20, and polyplex for siRNA
delivery21 could indeed release drug under
elevated redox potential in tumor. Long et al.

Figure 1.3. Chemical structure of

synthesized the disulfide-linked polyethylene

disulfide

glycol (PEG)−GSH conjugates 1 and 2 for GSH

polymer.
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linked-amphiphilic

delivery (Figure 1.2).22 PEG is employed to protect the GSH moiety from oxidation until
it is delivered into the cells. GSH is oxidized to GSSG during oxidative stress in cells,
thereby restricting the oxidation of other molecules. Therefore, it plays an antioxidant
role to protect cells from oxidative stress. When administered to the SH-SY5Y human
neuroblastoma cell line under oxidative stress induced by H2O2, 1 did not display
protecting activity against oxidative stress (Figure 1.2.). However, 2 was 100% effective
on inhibition of oxidative stress since 2 enabled to release GSH via the reduction of its
disulfide bond (Figure 1.2.). Further improvements in utilizing micelles that contain the
S–S bond were investigated by Thayumanavan et al.23 In this study, a disulfide bond was
exploited to conjugate the backbone chain to a hydrophobic alkyl chain resulting in the
formation of micelle-like nanoassembly in aqueous media. In the presence of GSH, the
doxorubicin loaded micelles were disassembled and thereby released the incorporated
drug upon the solubility change in polymer after disulfide cleavage. It was demonstrated
that the drug release from the micelles was dependent on the concentration of a reducing
agent, GSH. However, these micelle-based approaches were not feasible to release drug
release under tumor cell-relevant GSH levels. In addition, there have been many attempts
to obtain dual-sensitivity by combining pH-sensitivity with disulfide-based redoxsensitivity for selective tumor targeting.24 A disulfide group was also utilized for a redoxresponsive cross-linker to stabilize micellar structure and control the release of the
encapsulated cargo in response to D,L-dithiothreitol.25

7

1.2.2. Trimethyl-locked quinone propionic acid and DT-diaphorase
Trimethyl-locked quinone propionic acid (QPA) group can undergo two-electron
reduction by reducing agents to yield the respective hydroquinone propionic acid. The
hydroquinone is immediately transformed into its corresponding lactone via intra
molecular cyclization which eventually leads to the cleavage of any group linked through
the carboxyl functionality as shown in Scheme 1.1. QPA can be reduced not only by
chemical agents such as sodium dithionite and sodium borohydride but also by reductive
enzyme, DT-diaphorase.

Scheme 1.1. Chemical reduction of the trimethyl-locked QPA based redox-sensitive
material.

DT-diaphorase (NAD(P)H:quinone oxidoreductase (NQO) (EC 1.6.99.2) is a
cytosolic flavoprotein and was first isolated in 1958 by Lars Ernster.26 DT-diaphorase
catalyzes the two-electron reduction of diverse substrates including quinones, quinone
epoxides, aromatic nitro and nitroso compounds, azo dyes and Cr(VI) compounds using
NADH or NADPH as electron donors. DT-diaphorase has been regarded as a
chemoprotective enzyme capable of catalyzing the reduction and detoxification of
8

exogenous quinones. The enzyme is also known to be involved in the bioactivation of
molecules such as MMC into toxic DNA-damaging agents. This enzyme is interestingly
over-expressed in a number of tumor types, including non-small cell lung carcinoma,
colorectal carcinoma, liver cancers, pancreatic cancers and breast carcinomas, when
compared to normal tissues.27 In the case of non-small-cell-lung (NSCLC) tumors, DTdiaphorase activity determined using 2,6-dichlorophenolindophenol was found to be 123
nmol min-1 mg-1 compared to 6.4 nmol min-1 mg-1 in normal cells, a 20-fold increase28.
Since DT-diaphorase detoxifies and protects the cell from toxins and mutagens, it tends
to be expressed at higher levels in the early carcinogenic process. This upregulation may
involve in epigenetic factors such as hypomethylation of DT-diaphorase gene, elevation
of c-fos proto-oncogenes, altered promoter and/or repressor function.29 The previous
study reported that it might play a role in the stabilization of tumor suppressor protein
p53. Hence the last decade has seen increased focus on DT-diaphorase as an important
target in oncology and a QPA group has potential to develop into an effective redox
trigger to design redox-sensitive material in cancer research communities.
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Figure 1.4. Activation of QPA caged fluorophore by human DT-diaphorase to yield the
highly fluorescent dye, rhodamine.
Redox-triggered bioimaging probes composed of QPA have been synthesized to
release fluorescent indicators after the DT-diaphorase-mediated activation. McCarley and
coworkers have developed a QPA caged fluorophore using rhodamine (Figure 1.4.)30. It
demonstrated that the QPA-based imaging probe generated fluorescence in the presence
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of DT-diaphorase utilizing DT-diaphorase-positive human cancer cells. Moreover, redoxsensitive self-immolative fluorophore was synthesized with a QPA trigger group, an Nmethyl-p-aminobenzyl alcohol self-immolative linker and naphothalimide fluorophore to
detect DT-diaphorase levels for cancer diagnosis31. These studies investigated kinetics of
DT-diaphorase with the redox-sensitive fluorophores and verified the selectivity of the
QPA caged fluorophore to DT-diaphorase. However, monitoring fluorescence emission
from these QPA caged fluorophores has not been accomplished. Recently Liu et al.
synthesized DT-diaphorase-activatable theranostic prodrug which capable of assessing
fluorescent emission to detect DT-diaphorase level.32 Camptothecin, an inhibitor of
topoisomerase I, was selected as a fluorophore and its fluorescence was quenched by the
covalently attached QPA trigger via photoinduced electron transfer (PET). The
camptothecin released from the QPA caged fluorophore selectively destroyed the cancer
which overexpresses DT-diaphorase with high efficacy.

Figure 1.5. Activation of QPA caged self-immolative fluorophore by human DTdiaphorase to yield the highly fluorescent dye naphothalimide.
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Figure 1.6. Activation of QPA caged self-immolative fluorophore by human DTdiaphorase to yield the highly fluorescent dye naphothalimide.
In addition to the QPA caged imaging probes, the QPA trigger was applied to the
synthesis of prodrug for DT-diaphorase targeted release. A QPA-based aniline mustard
prodrug synthesized by Volpato et al. had showed that cyclized product and the active
drug were generated a time- and DT-diaphorase-dependent manner. The active drug
exerted cytotoxicity on T47D cells upon the reductive activation by oxidoreductases at
low oxygen concentration33. The QPA trigger was also exploited to design redoxtriggered liposomes which electrochemically release chemicals. The liposomes were
composed of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and a QPA trigger
attached to the head group of the lipid moiety.34 Chemical reduction-induced cyclization
of QPA head group on the liposomes led to conformational change in the supramolecular
assemblies, resulting in the release of encapsulated hydrophilic dye, calcein. Even though
the QPA trigger has been extensively investigated in the development of redox-sensitive
materials, it has never been introduced to a polymer network for drug delivery until our
12

group started to actively pursue the formulation of QPA based redox-sensitive polymer in
2012. The approach with polymeric nanocarriers to deliver drug is advantageous over
prodrugs and liposomes. Polymeric materials have a wide variety of available drug or dye
selection to be incorporated inside them in spite of its hydrophobicity. Furthermore, the
modification of polymers for further application in targeted delivery might be more easily
achieved than prodrug or liposomes.

1.2.3. Nitrocompounds and Nitroreductase
Nitroreductases (NTR) play an important role in catalyzing the reduction of
nitroaromatic compounds, which are wildly distributed in the environment.
Nitroreductase is a flavoenzyme bound with flavin mononucleotide (FMN) cofactor and a
homodimer of 24 kDA subunits expressed in Escherichia coli. It acts via a substituted
enzyme mechanism, whereby the bound FMN is first reduced by nicotinamide adenine
dinucleotide phosphate (NAD(P)H) and the NAD(P)+ produced dissociates. In the second
step, various substrates can bind to the enzyme and be reduced, in turn, by FMN. In the
case of nitroaromatic compounds, nitroreductase catalyzes the reduction of a nitro group
to hydroxylamine, which is subsequently converted to an amine in the presence of
NAD(P)H. The large electronic change resulting from the conversion of the electronwithdrawing nitro group to the electron-donating hydroxylamino group provides an
effective ‘switch’ mechanism for the activation of an inert compound and the subsequent
release of the active form of the agent. Based on this switch mechanism, various prodrugs
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or switchable imaging probes have been designed with nitro groups as substrates to be
triggered upon reduction by NTR.
According to previously reported NTR-catalyzed reactions, aromatic substrates
show relatively high reactivity with NTR caused by hydrogen bonding, π−π stacking
interaction, hydrophobic effect, and etc. The nitro groups in substrates can be reduced
first to a nitroso group, then a hydroxylamine group, and ultimately to an amino group. In
addition, the electron withdrawing group induces an electron-transfer process, quenching
the fluorescence emission of a substrate, and the reduction of nitro groups by NTR leads
to a change in fluorescence intensity. These fundamental concepts underpin an important
strategy in the design of fluorescent probes for NTR detection and NTR activatable
prodrugs.

2.3.1. Nitroreductase activatable prodrugs and sensors
The first identified NTR prodrug was 2,4-dinitrobenzamide, CB1954 that is also
known as tretazicar.35 It consists of a 2,4-dinitrobenzylamide ring linked at the 5-position
to an aziridinyl substituent. Both nitro groups were reduced by bacterial type I NTR
generating 2- and 4-hydroxylamine metabolites which have cytotoxic activities in
mammalian systems.36 In vitro analysis has shown not only that CB1954 functions as a
substrate for both T. brucei and T. cruzi NTR and but also that it blocks replication of the
mammalian forms of the parasites.36 Currently CB1954 proceeded to clinical trials in
combination with E. coli NTR as a potential gene-directed enzyme prodrug therapy
(GDEPT).37 A dinitrobenzamide mustard prodrug (PR-104) was also developed as an
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NTR activatable prodrug. PR-104 is the first developed tumor hypoxia-activated
(GDEPT independent) therapeutic agent and has advanced to multinational Phase II
clinical trials.38 The previous study has shown that PR-104 was tolerated by humans at up
to twenty times the maximum dose of CB1954 on a molar basis.38 Moreover, the
activated metabolites of dinitrobenzamide mustard prodrugs possess greater potency and
bystander effect than CB1954.39

2.3.2. p-nitrobenzyl-based prodrugs and sensors
Thanks to its high selectivity and sensitivity, application of NTR-catalyzed
reaction in the design of prodrug and imaging probes have attracted considerable
attention in the drug targeting field. Among various nitroaromatic compounds, however,
only a limited number of studies on a nitrobenzyl trigger had been carried out in the past.
Hu et al. first synthesized an NTR activatable phosphoramide mustard prodrug using a 4nitrobenzyl moiety as a redox-trigger.40 While the prodrug has low cytotoxicity in the
absence of NTR, it showed 167,500× selective cytotoxicity toward nitroreductaseexpressing V79 cells with an IC50 of 0.4 nM.40 It suggested that 4-nitrobenzyl
phosphoramide mustard is about 100× more active and 27× more selective than CB1954,
indicating that a nitrobenzyl functionality is a highly selective trigger to NTR. To explore
nitrocompound structure–activity relationships as substrates of NTR, Hu et al. have also
synthesized a series of nitrobenzyl phosphoramide mustards.41 The results implied that a
nitrobenzyl based prodrug offers the best enzyme activity and antiproliferative effect
against both mammalian and trypanosomatid cells. Hu’s group has also applied a
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nitrobenzyl group in the design of α-difluoromethylornithine (DFMO or Eflornithine)
prodrug.42 Moreover, Charkrapani’s group has synthesized a nitrobenzyl based
diazeniumdiolate

prodrug43.

Cell

viability

assays

for

DFMO

prodrug

and

diazeniumdiolate prodrug have revealed that cytotoxic effects towards cancer cell lines is
significantly enhanced in the presence of NTR.

Scheme 1.2 Chemical reduction of nitrobenzyl trigger based redox-sensitive prodrug.
In addition to the aforementioned nitrobenzyl trigger based prodrugs, various
selective imaging probes possessing a nitrobenzyl moiety have also been developed
during the past several years. Cui et al. have synthesized an NTR-activatable fluorescent
probe using a nitrobenzyl trigger and naphothalimide in 2011.44 The spectroscopic
evaluation using reducing agents including dithiothreitol, glutathione, cysteine,
homocysteine, NADPH and NTR verified that the probe was feasible to be reduced to
release fluorescence at 550 nm. Even though a nitrobenzyl trigger weakens an
intramolecular chare transfer of fluorophore, the nitrobenzyl trigger conjugated probe
emitted fluorescence at 475 nm and at 550 nm, before and after reduction, which works
in the relatively high energy region (400-650 nm) of the electromagnetic spectrum. To
minimize biological auto-fluorescence, a NTR-activatable sensor with a fluorescence
emission wavelength in the NIR region was recently developed by Shi et al.45 Cyanine
16

dyes were selected as a fluorophore with signals observed in the NIR region (>700 nm)
and the introduction of sulfonate groups to Shi’s dyes enable the sensor to improve water
solubility and prevent the aggregation of cyanate dye. It was demonstrated that the
nitrobenzyl trigger caged sensor did not emit significant fluorescence but strong NIR
emission at 708 nm in the presence of NTR. However, the antibacterial activity of this
sensor has not been tested. Despite the previous extensive investigation about the use of a
nitrobenzyl redox trigger for NTR activatable materials, such triggers have not been
applied for the development of bifunctional compounds, which can serve as a tool for
selective imaging and therapy.

1.3. Organization of the dissertation

Chapter 2 discusses a QPA trigger based redox-responsive polymer for potential
application in a tumor targeted drug delivery system. The synthesized polymers were
utilized to prepare hydrophobic drug loaded nanoparticles. Redox-triggered drug release
of nanoparticles was evaluated using sodium dithionite and their potential application in
the development of tumor targeted drug delivery system was delineated as well.

Chapter 3 includes a redox-responsive amphiphilic polymer comprising a QPA
redox trigger. Coupling of mPEG to a hydrophobic redox-responsive polymer provided
the amphiphilic polymer with its self-assembling capability to incorporate hydrophobic
drug into the core of micelles. The dimensional and chemical structural changes
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occurring to the micelles in the presence of a redox chemical were characterized to verify
if the drug releases in a redox-triggered manner. In vitro drug release kinetics and
cytotoxicity of micelles were also discussed.

Chapter 4 elaborates the synthesis and characterization of a nitrobenzyl redox
trigger caged NTR imaging probe. Selective uncaging of the probe via nitro reduction
was evaluated with live E. coli. for imaging. A potential therapeutic application of the
compound in photodynamic therapy was also addressed.

Last, in Chapter 5, we summarize the dissertation research work consisting of
those two materials prepared from redox triggers and discuss their challenges and future
research directions.
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CHAPTER 2
REDOX-RESPONSIVE PLYMERIC NANOPARTICLES FOR DRUG DELIVERY
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ABSTRACT
Bioresponsive polymeric nanoparticles have been extensively pursued for the
development of tumor-targeted drug delivery. Novel redox-sensitive polymeric
nanoparticles were prepared from a synthesized monomer containing trimethyl-locked
quinone propionic acid as a redox trigger. A hydrophobic cancer drug, paclitaxel, was
incorporated into the redox-responsive polymeric nanoparticles prepared from the
synthesize polymers. The particle size of nanoparticles was determined to be 180 nm (PD
= 0.138) by dynamic light scattering. The effect of redox stress on the nanoparticles was
evaluated with a chemical reductant, sodium dithionite demonstrating that the
nanoparticles released >80% of paclitaxel over 24 h at a simulated redox-state compared
to 26.5% to 41.2% release from the control. Cell viability studies revealed that the
polymer was non-toxic and the nanoparticles could release paclitaxel to suppress breast
cancer cell growth.
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2.1. INTRODUCTION
Cancer has been a major cause of mortality across the world.46 Tremendous
efforts have already been made to improve cancer therapy, including chemotherapy, in
conjunction with nanotechnology as well as bioimaging.47 Potent anticancer therapeutic
agents are generally non-selective and thus affect normal cells, leading to severe side
effects. Targeted drug delivery systems have been considered as a promising tool to
minimize the toxicity by distributing the cytotoxic drugs favorably to tumor sites in the
body. In particular, abnormal leaky tumor vasculatures and deficiency of lymphatic
drainage in tumor enable nanotechnology-based targeted drug delivery to favorably
accumulate cancer therapeutics in solid tumor while lessening their toxicity to normal
tissues.48 For selective drug release in tumor sites, stimuli-responsive polymer-based drug
delivery systems have been extensively explored.1 The bioresponsive delivery systems
can undergo conformational or physiochemical property changes and release
incorporated drugs in response to the signals stemming from tumor microenvironments
such as acidic pH2, altered oxidation-reduction (redox)3, over-expressed enzymes4 and
hyperthermia5.
Since redox changes associated with tumor hypoxia have been identified as a
viable biomarker for tumor progression and cancer drug resistance, reductive enzymes
overexpressed in tumor microenvironments, such as DT-Diaphorase (EC 1.6.99.2)7,
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provide an important methodology for selective tumor targeting. Various bioreductive
prodrugs that can be activated by the reductive enzymes specifically in hypoxic tumor
microenvironments have been reported and some of them are currently under clinical
trials.8 As demonstrated from aniline mustard protected with a bioreductive protecting
group, drug activation under hypoxia, tested on T47D cells, resulted in cytotoxicity.9a
However, the prodrug approach can be complicated with ubiquitous expression of various
reductive enzymes in normal cells.10 Even though redox-triggered liposomes that release
the incorporated molecule upon chemical reduction have been studied already,11e the
delivery platform based on the redox-sensitive polymeric nanoparticles have not been
conceived yet for targeted drug delivery applications. The approach with polymeric
nanoparticles to target hypoxic solid tumors would have advantages over the bioreductive
prodrugs and liposomes. They can be easily modified with the ligands that selectively
interact with the molecules expressed on cancer cells to achieve active targeting to cancer
cells. In addition, polymeric nanoparticles cannot be limited by the physicochemical
properties of the drugs to be loaded. Unlike to liposomes, polymeric nanoparticles can
easily adopt various cytotoxic drugs, either hydrophobic or hydrophilic for drug
targeting. Furthermore, the polymeric nanoparticles can be modulated for increased
circulation time and favorable accumulation in tumor.12
DT-diaphorase (NAD(P)H:quinone oxidoreductase (NQO1), EC 1.6.99.2) is an
obligate two-electron cytosolic reductase which reduces and detoxifies quinones and their
derivatives as a part of an electrophilic and/or oxidative stress-induced cellular defense
mechanism. DT-diaphorase is overexpressed in many cancerous tissues compared to
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surrounding normal tissues.49 In the case of non-small-cell-lung (NSCLC) tumors, a DTdiaphorase activity determined using 2,6-dichlorophenolindophenol was found to be 123
nmol min-1 mg-1 compared to 6.4 nmol min-1 mg-1 in normal cells, a 20-fold increase.
Since DT-diaphorase was known to activate quinone-bearing anticancer drugs, various
quinone derivatives have been studied as a viable component of bioreductive cancer
chemotherapeutics.50 In addition, quinone-based bioreductive prodrugs which release
active cytotoxic drugs have been designed to selectively target cancer cells by
overexpressed DT-diaphorase. Interestingly, trimethyl-locked quinone propionic acid
(QPA) has been known to readily undergo intramolecular cyclization by DT-diaphorasemediated two-electron reduction and release a lactone. Because of this unique property of
the QPA group, it has been extensively applied for cancer research as an efficient redox
trigger.51
Redox-triggered bioimaging probes consisting of QPA have been synthesized to
liberate fluorescent indicators after DT-diaphorase-mediated activation.52 Furthermore,
QPA has been applied for the synthesis of bioreductive prodrugs based on aniline
mustard53 and oxindoles54 for selective tumor targeting. Even redox-triggered liposomes
that electrochemically release chemicals have been designed with the QPA chemistry.52a
Chemical reduction-induced shedding of QPA from the liposome surface resulted in the
structural change of the supramolecular assemblies, which later destabilized the redoxsensitive liposomes to electrochemically release a hydrophilic fluorescent dye, calcein.
However, the QPA-based redox chemistry has never been applied for a polymeric drug
delivery system thus far. The approach to use QPA-based redox-sensitive polymeric
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nanoparticles is advantageous over the QPA-based prodrugs or liposomes to target the
redox stress in solid tumors. Polymeric nanoparticles can be easily modified with the
ligands that selectively interact with the molecules expressed on cancer cells to achieve
active targeting. In addition, the nanoparticles may be more flexible than the abovementioned liposome for the formulation of hydrophobic cancer drugs since they may
disrupt exquisitely balanced non-covalent interactions of QPA at the liposome surface.
Furthermore, the nanoparticles can easily achieve prolonged circulation in blood and
preferred accumulation in tumor by poly(ethylene glycol) (PEG) coupling.

Scheme 2.1. Chemical reduction of the redox-sensitive polymers based on trimethyllocked benzoquinone.
In this chapter, we describe a novel redox-sensitive polymer containing amino
groups protected with a QPA redox trigger, which is able to respond to the redox
variation with polymer property changes. The polymer is designed to release a lactone
from QPA and unmask free amino groups via the two-electron reduction mediated by
chemical agents, such as sodium dithionite (Na2S2O4). As a result, the reduced polymer
would have enhanced water solubility at neutral pH upon protonation of free amino
groups. Thus, nanoparticles prepared with the redox-sensitive polymer would be able to
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release incorporated drugs upon polymer hydration in response to redox changes
(Scheme 2.1). We first synthesize the monomers with QPA trigger to obtain redoxsensitive polymer. The polymers were utilized for the preparation of PTX-loaded
nanoparticles. The nanoparticles were evaluated for redox-triggered drug release under a
simulated redox state. In vitro cytotoxicity of nanoparticles was determined in human
breast tumor T47D and MDA-MB-231 cells to determine cancer cell-mediated drug
release.

2.2. EXPERIMENTAL
2.2.1.Materials
Methanesulfonic

acid,

2,3,5-trimethyl

hydroquinone,

methyl

β,β-

dimethylacrylate, 2-amino-1,3-propanediol, adipoyl chloride and glutaryl chloride were
obtained from Alfa Aesar (Ward Hill, MA). Adipoyl chloride and glutaryl chloride were
distilled under reduced pressure before the reaction. Paclitaxel (PTX) was purchased
from LC Laboratories® (Woburn, MA). Polyvinyl alcohol (PVA; Mw 30,000 - 70,000)
was obtained from Sigma-Aldrich (St. Louis, MO). All other chemicals purchased from
Fisher Scientific (Pittsburg, PA) were used as received.

2.2.2. Computational analysis
Polymer Construction
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QPA-based redox-sensitive polyester structures were constructed by combinations
between N-(1,3-dihydroxypropan-2-yl)-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa1,4-dien-1-yl) (monomer 1 in scheme 2.2, QPAMN) and two dicarboxylic acids, glutaric
acid and adipic acid. According to the nature of the repeating units, the polymers were
constructed head-to-tail in 3D using the polymer builder tool of Molecular Operating
Environment (MOE) software package (ver. 2011.10, Chemical Computing Group,
Montreal, Canada). We considered the three possible degrees of reduction –non-reduced,
partially reduced and reduced– of QPA groups because of their potential effects on
polymer solubility and drug release. Polymer chains of two molecular weights ~3000 and
~5000 Daltons were sketched.

Calculation of logP
The logP calculations used the weighted-method of ChemAxon suite
(MarvinSketch 5.6.0.1, 2011, www.chemaxon.com), which is a combination of three
algorithms, VG method (logP calculation according to various atom types)55, KLOP
method (group contribution approach)56 and PHYSPROP (based on a logP database).57
The logP calculated in this way is the arithmetic average of the three methods.

2.2.3. Synthesis of monomer
NHS-activated benzoquinone compound 4, NHS-QPA (scheme 2.2) was
synthesized as reported previously.9a To a mixture of 2-amino-1,3-propanediol (1.639 g,
18 mmol) and triethyl amine (5 mL) in isopropanol (100 mL), the synthesized compound
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4 (4.168 g, 12 mmol) in THF (50 mL) was added dropwise at room temperature. After
being stirred overnight at room temperature, the mixture was collected and concentrated
under reduced pressure. The crude compound was washed with NaHCO3 three times and
extracted by ethyl acetate (50 mL × 3), then dried over by sodium sulfate. The reductive
monomer 1 (yellow crystalline) was purified by recrystallization in ethyl acetate with an
isolated yields of 61.3% (2.379 g). NMR spectra were recorded on a Bruker
UltrashieldTM 400 PLUS at 400 and 100 MHz for 1H and 13C, respectively. The residual
solvent peak (δ = 2.50 or 7.24 for DMSO-d6 or CDCl3, respectively) were used as the
solvent residual references for 1H NMR spectra, and chemical shifts of the solvent peaks
(δ = 39.52 or 77.00 for DMSO-d6 or CDCl3, respectively) were used as the reference for
13

C NMR spectra.

Monomer 1, yellow crystal; mp 161–162 °C (from EtOAc) , 1H NMR (400 MHz,
DMSO-d6) δ = 7.54 (d, J = 8.3 Hz, 1H), 4.56 (t, J = 5.5 Hz, 2H), 3.60 (dt, J = 8.2, 5.6 Hz,
1H),3.32 (m, 4H), 2.71 (s, 2H), 2.01 (s, 3H), 1.90 (s, 3H), 1.87 (s, 3H), 1.32 (s, 6H); 13C
NMR (101 MHz, DMSO-d6) δ = 190.20, 186.85, 171.31, 154.94, 144.03, 136.07, 135.37,
60.13, 52.70, 47.58, 37.69, 28.06, 13.69, 12.77, 11.70; IR (neat, cm-1) 1528, 1600, 1638,
3333; Found: C, 63.20; H, 7.71. Calcd for C17H25O5: C, 63.14; H, 7.79.
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Scheme 2.2. Synthetic reactions for a trimethyl-lock quinone-based redox-sensitive
monomer.
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Figure 2.1. 1H and 13C NMR spectra of monomer 1 in DMSO-d6.
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Scheme 2.3. Schematic synthetic reactions for redox-sensitive polymer with QPA and
mechanism under reduction.

2.2.4. Synthesis of polymer
Freshly distilled glutaryl chloride (242.7 mg, 1.44 mmol) was diluted ten times
with dry THF and slowly added to the solution of monomer, QPAMN (464.3 mg, 1.44
mmol) in pyridine at room temperature (Scheme 2.3.). The reaction was further carried
on at room temperature overnight. After being poured into an excess amount of ethanol
and mixed for 6 hours, it was extracted with deionized (DI) water and later with CH2Cl2.
The collected organic phase was concentrated by a rotary evaporator and precipitated into
cold diethyl ether to obtain the crude product, (3a, 470.8 mg). The adipic acid based
polymer (3b, 571.4 mg) was synthesized with the same procedure shown above using 1.3
mL of pyridine monomer 1 (517.5 mg, 1.60 mmol) and dried adipoyl chloride (292.6 mg,
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1.60 mmol). The structures of the synthesized polymers, 3a and 3b, were elucidated by
1

H-NMR spectra using a Bruker Avance 400 MHz spectrometer. The molecular weight

and polydispersity index (PDI) of the synthesized polymers were determined with a
Waters gel permeation chromatography (GPC) system (Waters, Milford, MA). GPC
instrument is equipped with a binary pump (Waters 1525), a refractive index detector
(Waters 2414), and a Styragel HR4E column (300 × 7.8 mm ID, 5 µm particle size). The
measurement of the molecular weight was performed using HPLC grade THF as a mobile
phase at a flow rate of 1.0 mL min-1 at 25 °C. The molecular weight of the synthesized
polymers was determined with the calibration curve obtained using polystyrene standards
(600-50,000 Da). Under these conditions, retention times of 3a and 3b were 8.559 min
and 8.609 min, respectively.

Polymer 3a; 1H-NMR (400 MHz, CDCl3): δ 6.32 (1H, s), 4.38 (1H, s), 4.12 (2H, s), 4.06
(2H, s), 2.85 (2H, s), 2.38 (4H, t), 2.13 (3H, s), 1.95 (8H, m), 1.39 (6H, s).
Polymer 3b; 1H-NMR (400 MHz, CDCl3): δ 6.30 (1H, s), 4.37 (1H, s), 4.12 (2H, s), 4.06
(2H, s), 2.83 (2H, s), 2.36 (4H, t), 2.11 (3H, s), 1.95 (10H, m), 1.39 (6H, s).

2.2.5. Preparation of blank and PTX-loaded nanoparticles
The blank and PTX-loaded nanoparticles (NPs) were prepared by an single
emulsion method.58 NPs-3a from polymer 3a and NPs-3b from polymer 3b were obtained
through the same procedure. For preparation of PTX-loaded NPs, 40 mg of the
synthesized redox-responsive polymer and 4 mg of PTX were dissolved in 2 mL of
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CH2Cl2. This organic phase was slowly added to 18 mL of phosphate-buffered saline
(PBS, pH 7.4) containing 0.7% of PVA mixing under magnetic stirring. The mixture was
emulsified for 1 min in an ice bath by a probe sonicator (Qsonica, LCC. XL-2000,
Newtown, CT). The emulsion was stirred overnight at room temperature to evaporate
CH2Cl2. Aggregated NPs were filtered off with a 0.45 µm filter. The NPs were collected
from the filtered solution by centrifugation (VWR

TM

Galaxy 14D, 6,000 rpm, 15 min).

The NPs were washed twice with PBS, 20 mL each time, and later with 20 mL of DI
water to remove emulsifier. The produced suspension was lyophilized with the addition
of 20 mg of mannitol to obtain fine powder of NPs. To prepare blank NPs, the abovementioned procedures were employed except for leaving out PTX.

2.2.6. Characterization of blank and PTX-loaded NPs
The amount of PTX loaded in NPs was determined by dissolving a known weight
(1.05 mg) of freeze-dried drug loaded NPs into 1 mL of acetonitrile and was analyzed via
HPLC. The HPLC system is equipped with a Luna C18(2) chromatographic column
(Phenomenex, 150 x 4.6 mm, 5 µm), a binary pump (Waters 1525), and an auto-sampler
(Water 717). The mobile phase, a mixture of acetonitrile and water at 55/45% v/v, was
used at a flow rate of 1 mL min-1 after injecting a 20 µL sample.59 PTX was detected at a
retention time of 4.9 min using a UV detector (Water 2487) at 227 nm. The concentration
of released PTX was calculated using the calibration curve obtained from different
concentrations of PTX standard solutions in acetonitrile. The percentage of PTX
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incorporated into NPs was calculated by dividing the amount of incorporated PTX with
the initial PTX amount and multiplied by 100.
The size distribution and Z-average diameter of the NPs were determined by
dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments,
Worcestershire, UK). NP suspensions were diluted to a concentration of 1.25 g NP in 1
mL of DI water. NP sizes were measured before freeze-drying and after reconstituting the
NPs freeze-dried in the presence of mannitol in order to test the protective effect of
mannitol during drying NPs.
For scanning electron microscope (SEM) analysis, NPs were reconstituted at a
concentration of 1 mg mL-1 in DI water and homogeneously suspended by a 5 min
sonication. A 50 µL aliquot of the reconstituted sample was mounted on an aluminum
plate and dried. Then, the sample was sputter coated with gold and palladium. Quanta
FEG 650 (FEI) at an accelerating voltage of 10 or 15 kV was used to image NPs.60 The
polymeric nanoparticles were also characterized by transmission electron microscopy
(TEM) using a Tecnai T12 microscope (FEI, Hillsboro, OR) operated at 80 kV. Each
sample was sonicated for 5 minutes before being mounted on a carbon coated Formvar
cooper grid (400 mesh) and dried for 3 minutes. After wicking away excess solution and
air drying for 1 minute, samples were then negatively stained with uranyl acetate (2%
w/v) for 30 seconds prior to TEM imaging.
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2.2.7. In vitro drug release studies
In vitro PTX release from the prepared NPs was conducted using Na2S2O4 as a
reducing agent. An amount of PTX-loaded NPs-3b containing 10 µg of PTX was
suspended in 3 mL of PBS buffer (pH 7.4) containing 0.8 M of sodium salicylic acid. The
drug release was initiated by an addition of Na2S2O4 to the NP suspension. A 200-fold
molar excess of the reducing agent to QPA groups in the polymer was employed. Then,
the mixture was incubated in a shaking water bath (100 rpm) at 37 °C for 24 hours. At
designated times, a 150 µL aliquot of the NP sample was withdrawn from a vial after
spinning down the NPs and an equal volume of fresh reducing medium was added and
stirred into the NP solution. Samples were diluted with 150 µL of acetonitrile and the
supernatant samples obtained with centrifugation (13,000 rpm, 3 min) were injected into
the HPLC for analysis. The amounts of released PTX in the collected samples were
determined by the same HPLC method as described in 2.5 except for external standard.
The calibration curve was obtained from different concentrations of PTX standard
solutions in 50% (v/v) aqueous acetonitrile. For the quantitative determination of lactone
reduced from QPA groups, synthesized lactone was applied as external standard for
HPLC analysis as previously reported.57 The retention times of released lactone and PTX
were 4.98 min and 6.68 min, respectively, at 227 nm with an UV detector.
The drug release from NPs in cell media was also studied in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with/without 5% fetal bovine serum (FBS).
PTX-loaded NPs-3b (0.72 mg) were suspended into 1 mL of cell media incubating at 37
°C. At designated time point over 48 hours, 150 µL NP solution was withdrawn from the
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system and centrifuged at 10,000 rpm for 5 min to spin down NPs. Aliquots of 110 µL
NP solution from supernatant media were mixed to the same amount of acetonitrile (110
µL) to remove protein precipitate. The remaining 40 µL solution including precipitated
NPs was suspended with the same volume of fresh media and the suspension was added
to the system to keep constant volume. After completing the collecting samples, the NP
solution was mixed with the same volume of acetonitrile (1 mL) to measure the amount
of PTX remaining in the NPs. To determine the amount of PTX, all collected samples
were centrifuged to remove protein precipitate for the preparation of samples and HPLC
method was used in the same manner as for the measurement of the amount of drug
incapsulated in NPs.

2.2.8. Cell viability assay
Human breast tumor T47D and MDA-MB-231 cells obtained (ATCC, Manassas,
VA) were grown in DMEM/F12 medium containing 2.5 mM L-glutamine (Mediatech),
supplemented with fetal bovine serum (FBS, 10% v/v final concentration, Hyclone),
penicillin G (sodium salt, 50 units mL-1) and streptomycin sulfate (50 µg mL-1)
(BioWhittaker). Exponentially grown cells were plated at the density of 30,000 cells per
well into 96-well plates in a volume of 100 µL culture media and incubated at 37 °C in a
humidified environment (95% air, 5% CO2), as previously described.61 PTX was
dissolved in DMSO to obtain a 20 µM stock solution. PTX loaded NPs and blank NPs
were prepared fresh as 100 µM stock solutions in PBS (pH 7.4). After compound
treatment at the specified concentrations for 48 h, the cells were further incubated and
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cell viability was determined by the sulforhodamine B (SRB) method.62 Optical density
(OD) was measured at 490 nm with background absorption at 630 nm. Data were
normalized to the untreated control and presented as ‘% of control,’ using the formula.
Cell viability [% of Control] = (ODtreated/ODcontrol) × 100

2.2.9. Statistical analysis
Experimental measurements were triplicated for each sample. The results are
presented as mean ± standard deviation. The statistical analysis of experimental data
utilized the student’s t-test and statistical significance was considered for P-values < 0.05.

2.3. RESULTS AND DISCUSSION
2.3.1. Computational analysis and polymer synthesis
Molecular dynamics and molecular docking have been widely used in the process
of drug development as means to predict and rationalize the design of drug delivery
systems.63 Theoretical calculation of logP provides rapid evaluation of lipophilicity and
cellular penetration, which is widely used as a rational tool in the drug design process.
Two polymers were constructed by combinations of previously synthesized QPAMN and
dicarboxylic acids, glutaric acid and adipic acid. The main reason to select the two dicarboxylic acids was that NPs from the adipic acid-based redox-sensitive polymer have
demonstrated redox-triggered content release by solubility reversal upon polymer
reduction.57 Two polymer molecular weights, 3000 and 5000 Daltons, were considered to
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Table 2.1. Calculated logP values of QPA-based redox-responsive polymers at
different degrees of reduction. Two polymer molecular weights, 3000 Da and 5000
Da, were chosen for comparison.
MW ~5000
Non
reduced

Partially
reduced

MW ~3000
Fully
reduced

Non
Partially Fully
reduced reduced reduced

Polymer 3a

27.81

10.30

-6.29

18.87

7.21

-4.01

Polymer 3b

32.46

16.27

-0.55

19.72

10.53

-0.39

test lipophilicities using ChemAxon. The logP calculated from the arithmetic average of
the three ChemAxon logP methods including VG, KLOP and PHYSPROP showed the
lower values in the reduced forms. As shown in Table 2.1., fully reduced polymer with
molecular weight of < 5000 Da showed the decrease of logP values of 3a and 3b from
27.81 to -6.29 and from 32.46 to -0.39, respectively. The logP values of polymer with
MW < 3000 Da were similar and were lowered from 18.87 and 19.72 to -4.01 and -0.39
with the increase in reduction of polymers 3a and 3b, respectively. Reduction-dependent
logP change in the polymers is probably due to the exposure of hydrophilic amine group
upon removal of QPA. Especially, exposed primary amine groups would further lower
polymer logP by protonation.

2.3.2. Synthesis of monomer and polymers
Redox-sensitive polymer was designed from the monomer with a QPA trigger.
Initially,

benzoquinone

carboxylic

acid
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(β,β,2,4,5-pentamethyl-3,6-dioxo-1,4-

cyclohexadiene-1-propanoic acid) activated with N-hydroxylsuccimide was synthesized
according to the previous report.11a The activated compound was coupled with serinol (2amino-1,3-propanediol) as a redox-sensitive diol monomer to yield serinol-derived
polyester upon esterification with diacyl chloride. Serinol was selected for
polymerization because of proven biocompatibility of the serinol-derived polyesters.13 A
coupling reaction between trimethyl-lock benzoquinone succinimidyl ester and serinol in
a basic condition, successfully yielded diol monomer containing a QPA (QPAMN),
which was confirmed by 1H and

13

C NMR spectroscopy and elemental analysis. The

polymers 3a and 3b, designed for redox-triggered NPs were synthesized as illustrated in
Scheme 2.3. The molar ratio of QPAMN to diacyl chlorides was 1.0 to achieve the
highest possible polymer molecular weight which has reached 9,000 Da previously.
Polymer 3a synthesis yielded orange-yellow powders with a number-average molecular
weight (Mn) of 6980 Da (PDI = 1.5). Throughout this study, polymer synthesis has been
reproducible to show a very narrow molecular weight variation with a standard deviation
within 3% of polymer molecular weight. The proton NMR of polymer 3a in CDCl3
showed all the characteristic peaks and splitting in Figure 2.2.. The chemical shift of CH2-OH protons in QPAMN appearing at 3.32 ppm moved downfield to δ = 4.12 ppm
and 4.06 ppm, indicating ester formation upon polymerization. Furthermore,
characteristic methyl protons in QPAMN appearing at 1.41, 2.13 and 2.33 ppm were also
found in the polymer NMR spectrum, which showed the incorporation of the intact QPA
pendant group in the polymer backbone. Compared to the peak shapes in monomers,
corresponding peaks in the polymer were also broadened after the polymerization as
39

expected. The integration ratios of proton peaks on 1H-NMR spectrum were consistent
with the theoretical ratios of proton numbers in the polymer (Figure 2.3.)
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Figure 2.2. 1H NMR spectrum of the redox-responsive polymer 3a.
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Figure 2.3. 1H NMR spectrum of the redox-responsive polymer 3b.

2.3.3. Preparation of redox-responsive NPs
Redox-responsive NPs were prepared in the presence or absence of PTX from the
synthesized polymers. An emulsion method using PVA was employed to obtain NPs with
controlled particle sizes. Although particles smaller than 500 nm can be passively
accumulated in tumor by the enhanced permeability and retention (EPR) effect, NPs with
particle sizes are less than 200 nm are generally considered as ideal for targeted drug
delivery.64 Emulsifying hydrophobic polymers and subsequent solvent evaporation have
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frequently yielded NPs suitable for tumor-targeted drug delivery.65 The mean size of
NPs-3a was determined to be 246.0 nm (PDI = 0.12) and 238.8 nm (PDI = 0.15), for the
blank NPs and PTX-loaded NPs, respectively, as summarized in Table 2.2. It was found
that the use of surfactants for the preparation of redox-responsive NPs affected particle
size. Tween 80 and Pluronic F68 indeed resulted in particle sizes ranging from 400 nm to
830 nm (data not shown). The nonionic stabilizers might differently affect the stability of
the oil-in-water emulsions of the redox-responsive polymers. Droplet sizes of the
emulsions could be an important factor for the size of final hardened polymer NPs. The
sizes of our redox-responsive NPs were comparable to the particle sizes obtained with
poly(D,L-lactide-co-glycolid) (PLGA).66 The size of PLGA (MW 75,000-120.000) NPs
prepared with Pluronic F68 was 461 ± 10 nm, which was larger than the 284 ± 6 nm
obtained with PVA.66 This result indicated that PVA in CH2Cl2 could decrease interfacial
tension more than Pluronic F68 did and, thus, lead to smaller particles size. The increase
in size of obtained NPs was observed due to the aggregation of NPs when using Tween
80 and similar observations were also reported on the formation of poly(D,L-lactic acid)
NPs emulsified with Tween 80.66
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Figure 2.4. Size distribution of blank nanoparticles (A) and paclitaxel incorporated
nanoparticles (B) by dynamic scattering method (DLS)

PTX loading into NPs-3a was determined to be 45% (w/w) as summarized in
Table 2.3. However, NPs-3b resulted in an enhanced drug loading of 77% (w/w). It
looked as though an additional carbon in the polymer repeating unit in polymer 3b might
be attributed to the difference in drug loading in two kinds of NPs. As previously
observed, drug loading into polymer particles is closely related to drug solubility in the
polymer. It is speculated that polymer 3b may have greater miscibility with PTX than
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polymer 3a because of greater hydrophobicity as predicted by theoretical logP
calculations (Table 2.1.).
Aggregation of hydrophobic NPs during freeze drying has commonly been
observed.67 Carbohydrate stabilizers such as sucrose, lactose, glucose, sorbitol, and
mannitol have been routinely employed to prevent the product from undergoing the stress
that could destabilize colloidal suspension, which is generated during the freeze drying
process.68 For the freeze-drying of redox-sensitive polymer NPs prepared from QPAbased polymer, mannitol was added to minimize particle aggregation and improve the
handling properties of the dried NPs. It should be noted that mannitol has been widely
used as a cryoprotectant in the formulations of biotechnology products which are
currently in the market.69 It has also been known that mannitol tends to crystallize during
freeze-drying process resulting in powdery and dry products, which usually improves
handling property.70 The protective effect of mannitol during freeze drying was examined
by particle size measurements before and after nanoparticle drying. The size of redoxresponsive NPs-3b before drying was determined to be 220.60 ± 21.56 nm (PDI = 0.16 ±
0.07). Nanoparticle size slightly increased to 269.83 ± 21.56 nm (PDI = 0.24 ± 0.05) after
reconstitution of the dried NPs into water (summarized in Table 2.2). This slight particle
size increase may be due to hydration of NPs. The redox-responsive polymer NPs seemed
to be aggregated by inter-particular hydrophobic interactions during freeze drying
without mannitol.71 It appears that nanoparticle aggregation was prevented by the
presence of mannitol which can hold water and fill spaces between NPs during the drying
process. Drug loading did not noticeably diminish the protective role of mannitol to
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Table 2.2. Mean sizes of prepared redox-responsive polymer nanoparticles and drug
loading efficiency into the nanoparticles. Mannitol was used to stabilize the particles
during freeze-drying. Paclitaxel was used as a model drug. Data presented as mean ±
standard deviation of three independent experiments.

Blank NPs-3a

Size (nm)
drying with
mannitol-free
mannitol
246.03 ± 42.58
322.07 ± 28.59

PTX loded NPs-3a

238.8 ± 20.49

257.67 ± 43.89

Blank NPs-3b

220.60 ± 21.56

269.83 ± 26.57

PTX loded NPs-3b

256.47 ± 9.55

293.17 ± 13.21

NPs

Drug loading
efficiency
(w/w)
45%
77%

hinder particle aggregation. In the case of PTX-loaded NPs-3b, particle size was
marginally increased from 256.47 ± 9.55 nm (PDI = 0.08 ± 0.03) to 293.17 ± 13.21 (PDI
= 0.17 ± 0.06) for wet NPs before drying and reconstituted particles after freeze-drying,
respectively, in the presence of mannitol (Table 2.2). In addition, lyophilized NPs have
maintained their stability over an eight week period (summarized in Figure 2.5).
Reconstituted PTX-loaded NPs-3b have shown a modest particle size increase from 293.2
nm to 346.4 nm over an eight week incubation at 37 °C (Figure 2.5). Interestingly, a
noticeable change in particle size modification was observed with blank NPs, wherein the
size of NPs increased from 269.8 nm to 558.5 nm in 4 weeks. The particle size further
increased to 682.8 nm in another 4 weeks. The hydrophobic drug might have contributed
to an improved stability of PTX-loaded NPs.
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Figure 2.5. Size distribution of blank NPs-3b (□) and PTX-loaded NPs-3b (■) suspended
in DI water and incubated at 37 °C over eight weeks. Data shown as mean ± SD (n = 3).
Other NPs prepared from gelatin, poly(D,L lactide-glycolide) and lipids have also
demonstrated a similar mannitol-mediated protective effect with no significant particle
size alteration after freeze drying.72 In addition, as shown in Figure 2.6., mannitol was
well integrated with the redox-responsive NPs-3b. The morphologies of NPs with or
without PTX loading after drying in the presence of mannitol were different from that of
freeze-dried mannitol as confirmed by SEM images. SEM images of dried mannitol
revealed spherical particles with relatively uniformed size as well as rounded morphology
(Figure 2.6.(C)). On the other hand, the microscopic images of dry NPs (Figure. 2.6.(A)
and (B)) showed that mannitol has been integrated well with polymer NPs by showing
chunks rather than segregated mannitol spheres. Mannitol integrated with the NPs might
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be distributed between particles as a space filler or as a coat on their surface, which
prevents inter-particular hydrophobic interactions between NPs.

Figure 2.6. Scanning electron microscopy images of freezing dried nanoparticles
prepared with mannitol (A) PTX-loaded NPs-3b and (B) Blank NPs-3b, and (C) Freezedried mannitol.
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Figure 2.7. The TEM images of blank nanoparticles (left) and paclitaxel incorporated
polymeric nanoparticles (right)

2.3.4. In vitro paclitaxel release
The effect of redox stress on the nanoparticles was tested with a chemical
reductant, sodium dithionite (Na2S2O4). It was expected that sodium dithionite would
reduce QPA to leave free amine groups on the polymer, which would result in physicochemical changes in nanoparticles that would induce nanoparticle swelling or
dissolution at pH 7.4. Sodium dithionite-induced reduction dramatically increased the
hydrodynamic diameter of the nanoparticles from 178 nm in a turbid solution to 29.3 µm
in a transparent solution, a size beyond the measurable limit by the Zetasizer as shown
in Fig. 2.8. The size changes might have resulted from the protonation of free amine
groups in serinol of which pKa is around 9.15.
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Figure 2.8. Change in nanoparticle size in the presence of sodium dithionite determined
by DLS.

PTX release from the redox-responsive NPs was studied under a redox state
simulated with a chemical reducing agent, sodium dithionite. Sodium dithionite has been
frequently adopted in physiology experiments as a means to lower solutions’ redox
potential (E° -0.66V at pH 7 at 0.35 nM73) and to mimic a reductive environment. Figure
2.9.(A) shows that QPA-based redox-responsive NPs were able to release incorporated
drug upon pendant QPA group reduction. Under a redox state simulated with sodium
dithionite, the amounts of released PTX were significantly greater than PTX release in
PBS (P < 0.05 for NPs-3a and NPs-3b at 15 min, P < 0.01 at 3 hours, in Figure 2.9.(A)).
Cumulative percentage of PTX released from two different NPs was more than 80% after
a 24 h incubation under the redox state. However, only 41.2% and 26.5% of incorporated
PTX were released from the NPs in the absence of the reducing agent. It was interesting
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to note that the NP from adipic acid-based redox-responsive polymer 3b showed PTX
release comparable to that from NPs-3a.57 Lactone released from reduced QPA was
consistent with PTX release indicating PTX release was mediated by lactone release.
Facilitated PTX release under the redox state can be attributed to QPA reduction which
deprotects amine groups in the polymer backbone. Free amine groups exposed upon
intramolecular cyclization of QPA could increase polymer solubility upon protonation at
pH 7.4, which might result in nanoparticle swelling. Theoretical calculations of
hydrophobicity reduction upon polymer reduction, from 27.81 to -6.29 and from 32.46 to
-0.55 for polymers 3a and 3b, respectively (Table 2.1), also led to the prediction of
polymer solubility increasing upon polymer reduction. In addition, exposed amine groups
might contribute to the hydrolysis of the polyester backbone in a base-catalyzed
manner.74 As expected, NPs in the control release medium containing no reducing agent
did not release quinone lactone at all (Figure 2.9.(B). It is worthwhile to mention that
NPs-3b showed lower initial PTX release than NPs-3a. The difference in burst PTX
release from the NPs can be attributed to the polymer solubility difference. As previous
theoretical calculations of polymer property predicted, polymer 3a is less hydrophobic
than polymer 3b which has one more carbon in polymer repeating unit. Predicted logP
values (Table 2.1) for non-reduced polymer 3a and 3b were 27.81 and 32.46, respectively
at a molecular weight of 5000 Da. It seemed that more hydrophobic polymer NPs-3b
demonstrate the lower initial burst. Considering theoretical polymer property prediction
and experimental drug release under a simulated redox state, NPs-3b would be more
suitable for drug delivery applications, with a low burst drug release but maximized
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content release upon polymer reduction. However, drug release from the NPs by cancer
cell-overexpressing redox enzymes should be further tested and confirmed before the
implementation of the novel redox-responsive polymer NPs for tumor-targeted drug
delivery.

Figure 2.9. (A) In vitro redox-responsive release of PTX and (B) release of lactone from
reduced QPA when incubated in the reductive media including Na2S2O4 (● and ■) and at
control media (○, □ and x) at 37 °C from NPs-3a (● and ○) and from NPs-3b (■ and □).
The results represent the mean ± SD (n = 3).

2.3.5. In vitro cytotoxicity
Concentration-dependent cell cytotoxicity studies were performed to determine
the effects of PTX–loaded redox-responsive NPs on the proliferation/viability of human
breast tumor T47D and MDA-MB-231 cells. PTX-loaded and blank NPs-3a were used as
positive and negative controls for the study, respectively. At the lower concentration
range (0.01 µM or less), almost no cytotoxicity for both cell lines could be detected as
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shown in Figure 2.10. When the concentration was at 1 µM, the cell viability of T47D
cell line with the incubation of PTX and PTX loaded NPs were 69% and 73%,
respectively, while the result of cytotoxicity with blank NPs showed its less toxicity as
91% of cell viability in Figure 2.10 (A). The cell experiment for MDA-MB-231 cell line
in Figure 2.10 (B) also showed similar cell viability, in which 48%, 50%, and 97% of cell
viability were observed for plain drug, PTX loaded NPs, and blank NPs, respectively.
PTX loaded NPs inhibited cell proliferation and viability to the comparable extent as that
observed in the presence of PTX. The particle itself did not affect cell
proliferation/viability at all concentrations tested indicating that all incorporated PTX has
been released from NPs to limit cell growth.

Figure

2.10.

Effects

of

PTX-loaded

NPs

on

human

breast

tumor

cell

proliferation/viability determined by SRB method: (A) T47D cells. (B) MDA-MB-231
cells. Exponentially grown T47D and MDA-MB-231 cells were exposed to the different
concentration of PTX-loaded NPs, blank NPs, and PTX for 48 h under normoxic
condition (95% air: 5% CO2). The percentage of viable cells was normalized to values
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obtained from untreated control under normoxia conditions, and presented as “%
Control”. Data shown are average ± standard deviation (n = 3).
Aside from in vitro cellular study, in vitro drug release from the NPs was
examined to confirm culture cancer cell-mediated drug release from NPs using serumfree cell culture media and culture media supplemented with 5% FBS presented in Figure
2.11. The amounts of drug released from the NPs over 48 h ranged from 12.58% to
15.71% and from 10.89% to 14.66% in serum free DMEM and in DMEM with 5% FBS,
respectively. In addition, the analysis of remaining NPs showed considerable amounts of
PTX left in the NPs, indicating that FBS might contribute to drug release in part but not
all. The amounts of drug found in the NPs were 86.05% and 53.67% in serum free
DMEM and DMEM with 5% FBS, respectively. The reason for less drug retention in the
presence of FBS might be the enzymes in FBS. It has been known that FBS contains a
mixture of enzymes including esterases and proteases which are able to degrade polyester
backbone in the QPA-based redox-responsive polymer. Proteins in FBS, 23 g L-1 of
albumin and 38 g L-1 of total protein, may also be able to affect polymer degradation,
nanoparticle stability or PTX protein binding.75 Indeed, PTX was reported to significantly
bind to protein in cell culture media, which was PTX concentration dependent. PTX was
known to result in 78.6 ± 2.7% protein binding at a concentration of 0.5 µg mL-1 in cell
culture medium with 9% FBS and PTX binding to proteins decreased to 20.2 ± 1.4 % as
concentration of PTX increased to 15 µg mL-1. The PTX protein binding might
overestimate PTX release in FBS containing DMEM. However, taking cell cytotoxicity
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results and in vitro drug release in culture media together, cultured cancer cells could
release PTX from the redox-responsive NPs.

Figure 2.11. In viro PTX release from NPs-3b in different cell culture media: serum-free
cell culture media (○) and the media supplemented with 5% FBS (●). Data shown as
mean ± SD (n = 3).

2.4. CONCLUSIONS
Novel redox-sensitive polymeric nanoparticles were prepared from a synthesized
monomer containing quinone propionic acid as a redox sensitive group. A hydrophobic
cancer drug, paclitaxel, was incorporated into the polymeric nanoparticles and released
by sodium dithionite-mediated reduction in a triggered manner. Cytotoxicity assay using
cultured human breast tumor cell lines demonstrated that cancer cells could release
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incorporated drug from the NPs. These redox-sensitive NPs may be useful as delivery
platforms for cytotoxic cancer drugs.
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CHAPTER 3
REDOX-RESPONSIVE POLYMERIC MICELLES FOR DRUG DELIVERY
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ABSTRACT
A novel redox-responsive amphiphilic polymer was synthesized with bioreductive
trimethyl-locked quinone propionic acid for a potential triggered drug delivery
application. The aim of this study was to synthesize and characterize the redoxresponsive amphiphilic block copolymer micelles containing pendant bioreductive
quinone propionic acid (QPA) switches. The redox-responsive hydrophobic block
(polyQPA), synthesized from QPA-serinol and adipoyl chloride, was end-capped with
methoxy poly(ethylene glycol) of molecular weight 750 (mPEG750) to achieve a redoxresponsive amphiphilic block copolymer, polyQPA-mPEG750. PolyQPA-mPEG750 was
able to self-assemble as micelles to show a critical micelle concentration (CMC) of 0.039
% w/v (0.39 mg mL-1, 0.107 mM) determined by a dye solubilization method using 1,6diphenyl-1,3,5-hexatriene (DPH) in phosphate buffered saline. The mean diameter of
polymeric micelles was found to be 27.50 nm (PI = 0.064) by dynamic light scattering.
Furthermore, redox-triggered destabilization of the polymeric micelles was confirmed by
1

H-NMR spectroscopy and particle size measurements in a simulated redox state.

PolyQPA-mPEG750 underwent triggered reduction to shed pendant redox-responsive
QPA groups and its polymeric micelles were swollen to be dissembled in the presence of
a reducing agent, thereby enabling the release of loaded model drug, paclitaxel. The
redox-responsive polyQPA-mPEG750 polymer micelles would be useful as a drug
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delivery system allowing triggered drug release in an altered redox state such as tumor
microenvironments with an altered redox potential and/or redox enzyme upregulation.
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3.1. INTRODUCTION
Drug delivery system holds great promise as a tool to improve pharmacokinetics
and therapeutic efficacy of drugs76. In particular, anti-cancer drugs have been an active
subject of targeted delivery aiming at microenvironment changes occurring at tumor sites
77

. Nanotechnology is emerging as a promising tool for cancer targeted drug delivery

system because of their favorable distribution at tumor sites based on enhanced
permeability and retention
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. However, important challenges associated with drug

delivery systems such as target tissue specificity and drug release rate at systemic subcellular levels to achieve maximum therapeutic efficacy but minimal toxicity often
remain as obstacles to their successful translation into clinical outcomes. One approach to
overcome these limitations would be designing multifunctional materials with
consideration of meaningful pathophysiological changes occurring at a target site. In
recent years, various drug delivery systems were explored for their properties to release
encapsulated drug in a triggered manner in response to abnormal tumor
microenvironments such as acidic pH79, over-expressed enzymes80, hyperthermia81 and
altered redox states 82 compared to normal tissues.
In cellular systems, redox homeostasis plays pivotal roles in the maintenance of
cellular functions. Intracellular compartments maintain a certain redox gradient compared
to the extracellular environment, providing an exciting target for selective intracellular
chemical release. The redox gradient between intracellular and extracellular
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compartments in a wounded site is significantly greater than that in healthy tissues, which
is modulated by intricate networks of redox signaling pathways adapting internal
environment to the extracellular changes

83

. Redox agents expressed during the

intracellular redox-regulatory processes serve as indicators of the redox status. Redox
switch materials inspired by these redox agents are appealing tools to be exploited into
drug delivery systems which enable to release drugs by triggering chemical/physical
changes upon exposure to an altered reductive environment in cancer 84.
Various redox-switches utilized to create multifunctional materials for drug
delivery applications have frequently been based on diselenide and disulfide bonds.85
Trimethyl locked quinone propionic acid (QPA) group has also been of interest, as they
can be reduced to form lactone by intramolecular cyclization of hydroquinone via the two
electron reduction86. The reduction of the QPA subunits associated with synthetic
materials has been demonstrated by the adoption of the simulated redox states not only
with chemical agents such as dithionite and borohydride, but also with reductases such as
DT-diaphorase (NAD(P)H:quinone oxidoreductase (NQO1), EC 1.6.99.2)87. It is
interesting to note that DT-diaphorase, a two electron reductase, is highly expressed in
several cancerous tissues88. Tumors such as non-small cell lung cancer and pancreatic
cancers have shown to express high levels of DT-diaphorase relative to normal tissue, as
much as a 20-fold increase28. Hence, QPA-based materials provide a wide range of
redox-triggered architectures to tune the cleavage of the redox-switch for targeted drug
delivery to tumors86, 89. Volpato and coworkers prepared an aniline mustard prodrug
containing QPA group to prove the prodrug activation in vitro selectively by DT61

diaphorase, comparing to other reductase such as cytochrome p450 reductase86. Their
study has demonstrated that active aniline mustard could be released from the prodrug via
DT-diaphorase-mediated bioreduction. Redox-sensitive liposomes comprising a QPA
head group and dioleoyl phosphatidylethanolamine (DOPE) lipids have also been
prepared by Ong et al.
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. The researchers have demonstrated that rapid lysis of the

liposomes resulted in the release of incorporated calcein via liposomal structural
destabilization upon reduction of QPA head group by dithionite. Recently our group has
developed redox-responsive polymeric nanoparticles (NPs) with pendant QPA redox
triggers which aqueous solubility could be reversed upon QPA reduction. These QPAbased redox–responsive NPs were able to release incorporated paclitaxel under a redox
state simulated with dithionite. Additionally, in vitro cytotoxicity study has confirmed
that these NPs could release paclitaxel in the presence of human breast tumor T47D and
MDA-MD-231 cells. Although these redox-responsive NPs offer advantages as a tumor
targeted drug delivery system, they were noticeably aggregated in aqueous environment
because of hydrophobic nature of the polymer82, 90. It has been found that hydrophobic
polymer nanoparticles have limitations including poor stability in blood during
circulation and high cytotoxicity for their potential in vivo applications
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. To overcome

these limitations, we intended to obtain the PEG grafted polymeric drug delivery system
as the alternative approach mainly because of well-established non-fouling property of
PEG that prevent the adsorption of plasma protein or the opsonization.92
In this paper, we describe a novel amphiphilic block copolymer which is designed
to possess QPA redox switches in the hydrophobic block while hydrophilic PEG block is
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expected to increase physical stability of resultant NPs. Considering the capability of
QPA reduction

in the presence of meaningful tumor-associated redox changes, we

anticipate that polymer micelles consisting of QPA redox switches can be destabilized by
a solubility reversal occurring in the hydrophobic polymer block of the copolymer due to
the release of pendant QPA groups. To our knowledge, this is the first study reporting
the incorporation of QPA redox switches in the polymeric micellar system for a drug
delivery application.

3.2. EXPERIMENTAL
3.2.1. Materials
Methanesulfonic

acid,

2,3,5-trimethyl

hydroquinone,

methyl

β,β-

dimethylacrylate, 2-amino-1,3-propanediol, and adipoyl chloride were obtained from
Alfa Aesar (Ward Hill, MA). Adipoyl chloride was distilled under reduced pressure
before the reaction. Paclitaxel (PTX) was purchased from LC Laboratories® (Woburn,
MA). Methoxy poly(ethylene glycol) of molecular weight 750 (mPEG750) from SigmaAldrich (St. Louis, MO) was used after distillation. Acetone-d6 (99.9%, Cambridge
Isotope Laboratories, Inc., Andover, MA) and deuterium oxide (99.8%, Acros) were used
for NMR measurements as received. Human DT-diaphorase and reduced dipotassium salt
β-nicotinamide adenine dinucleotide (β-NADH) were purchased from Sigma-Aldrich (St.
Louis, MO). All other chemicals purchased from Fisher Scientific (Pittsburg, PA) were
used as received.
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Scheme 3.1. Reaction scheme for the synthesis of redox-responsive amphiphilic block
copolymer, polyQPA-mPEG750, with QPA redox-switches.

3.2.2. Synthesis of amphiphilic redox-sensitive polymer (polyQPA-mPEG750)
PolyQPA-mPEG750 was synthesized in a two-step reactions shown in Scheme
3.1.. First, redox-responsive hydrophobic block, polyQPA, was synthesized as reported
previously82, 90. Briefly, fresh distilled adipoyl chloride diluted in anhydrous THF was
slowly added into a solution of the monomer, QPA-serinol, at a molar ratio of 1:1 in
pyridine (10 times molar amount of adipoyl chloride) at room temperature and stirred for
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30 min. After further polymerization under dry nitrogen at room temperature overnight,
an additional amount of adipoyl chloride (another 10% of initial molar amount) in THF
was charged to the reaction mixture and stirred for another six hours. Next, mPEG750 was
dried by azeotropic distillation using toluene to end-cap polyQPA. Dried mPEG750 in
THF was added to polyQPA at a molar ratio of 10:1 and the end-capping reaction was
proceeded for another 16 h. Resultant polyQPA-mPEG750 was precipitated in an excess
amount of ether and the crude polymer was purified further by rinsing three times with
methanol to remove unreacted mPEG. The final product polyQPA-mPEG750 was yielded
as yellow solid (62.1%).
1

H-NMR (CDCl3): δ ppm: 4.37 (14H, s), 4.12 (28H, s), 4.06 (28H, s), 3.64 (90H, s), 3.30

(6H, s), 2.83 (28H, s), 2.36 (56H, t), 2.12 (42H, s), 1.95 (56H, m), 1.39 (14H, s).

3.2.3. Characterization of polyQPA-mPEG750
The chemical structures of the polyQPA-mPEG750 were identified with H1-NMR
spectrum using a Bruker Avance 400 MHz spectrometer. The NMR spectra were
measured in CDCl3. The molecular weight and polydispersity index (PDI) of the
synthesized copolymer were determined with a Waters gel permeation chromatography
(GPC) system (Waters, Milford, MA). The GPC instrument is equipped with a binary
pump (Waters 1525), refractive index detector (waters 2414), and a Styragel HR4E
column (300 × 7.8 mm ID, 5 µm particle size). HPLC grade tetrahydrofuran (THF) was
run as a mobile phase at a flow rate of 1.0 mL min-1 at 25 °C. Number (Mn) and weight
average (Mw) molar masses were determined using Breeze software. The molecular
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weight of the copolymer was calculated using a calibration curve obtained from
polystyrene standards (Polysciences, Inc., Warrington, PA) of molecular weights ranging
from 600 to 50,000 g mol-1 in THF.

3.2.4. Preparation of polymeric micelles
Drug-free and PTX-loaded polymeric micelles were prepared by a method of a
solid dispersion technique with a minor modification93. Briefly, PTX (32.2 mg) and
polyQPA-mPEG750 (150 mg) were completely dissolved in 2 mL of acetonitrile. After
evaporation of the organic solvent using a rotary evaporator, remaining organic solvent
was further removed by a vacuum pump overnight to obtain the molecularly dispersed
PTX in polymer matrix. Three milliliters of phosphate buffered saline (PBS, pH 7.4)
were added to the mixture to obtain micellar solution by hydration. After being stirred
overnight in dark at room temperature, the solution was filtered through a 0.2 µm filter to
remove the unincorporated drug aggregates, followed by lyophilization. The blank
micelles were prepared by the same procedure without PTX.
The loading efficiency of PTX in the micelles was determined by the HPLC
method previously reported to analyze the amount of PTX in QPA polymer NPs90. The
drug loading efficiency (%) was calculated according to the following formula.
PTX loading (%) = (amount of loaded PTX/amount of initially added PTX) × 100
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3.2.4. CMC measurement
The critical micelle concentration (CMC) of the polymer was determined by a dye
solubilization method using 1,6-diphenyl-1,3,5-hexatriene (DPH)94. Briefly, serially
diluted polymer solutions in a concentration range of 1.0 × 10-4 to 1.0 wt.% were
prepared with PBS. Next, 25 µL of 0.4 mM DPH solution in methanol was added into 2.5
mL of each polymer solution. The mixture was sonicated for 1 min and equilibrated for
24 h in a dark place. Measurements of UV absorption for each solution were taken on a
Genesys 6 UV-Visible scanning spectrophotometer (Thermo Scientific, Massachusetts) at
wavelengths of 377 and 391 nm. The absorbance difference at 377 and 391 nm was
plotted against polymer concentration. The CMC of polyQPA-mPEG750 was determined
by reading the polymer concentration at which the extrapolated two lines cross over.

3.2.5. Particle size measurements and redox-responsive polymer degradation
The Z-average diameter and polydispersity index (PI) of polyQPA-mPEG750
micelles were determined by dynamic light scattering using a Zetasizer Nano ZS
(Malvern Instruments, Worcestershire, UK). A polyQPA-mPEG750 solution at a
concentration above its CMC was prepared to allow self-assembling into micelles in
PBS.
The effect of QPA reduction on the micellar structure was tested with a chemical
reducing agent, sodium dithionite (Na2S2O4). QPA lactone release was identified by 1HNMR spectrum. A polyQPA-mPEG750 solution at a concentration of 1.5% (w/v) was
prepared for the NMR measurement using a co-solvent of acetone-d6 and deuterium oxide
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at a volume ratio of 1:2. The NMR spectrum of release QPA lactone was measured on
the NMR spectrophotometer and compared with that of QPA lactone control synthesized
during polymer synthesis 86. The NMR spectra were periodically taken up to 3 h after the
addition of sodium dithionite.

3.2.6. Redox-triggered QPA lactone release from polyQPA-mPEG750 micelles
QPA lactone release from the micelles was examined by challenging polyQPAmPEG750 micelles with two different redox-triggers, sodium dithionite and DTdiaphorase. A polyQPA-mPEG750 stock solution at a concentration of 10 mg mL-1 (1%)
in PBS was prepared and diluted to obtain polymer solutions at concentrations of 0.01%
and 0.5%. Fifteen milligrams of sodium dithionite resulting in a final concentration of 29
mM was added to 3mL of each polyQPA-mPEG750 solution. In the case of enzymatic
reduction of QPA, five units of DT-diaphorase and bovine serum albumin (0.007%) were
added to each PolyQPA-mPEG750 solution. After an addition of an amount of β-NADH
to achieve a final concentration of 2 mM, 150 µL of the medium was collected and mixed
into 150 µL of acetonitrile at predetermined time points. All samples were tested in
triplicate and the study was carried out in a water bath equilibrated at 37 °C. Amounts of
QPA lactone released upon reduction were analyzed using the HPLC method previously
reported. A HPLC system equipped with a Luna C18(2) HPLC column (Phenomenex,
150 x 4.6 mm, 5 µm), a binary pump (Waters 1525), and an auto-sampler (Water 717)
was used to run a mixture of acetonitrile and water at 55/45% v/v as a mobile phase at a
flow rate of 1 mL min-1 after injecting a 20 µL sample
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. Released QPA lactone was

detected at a wavelength of 227 nm on a UV detector (Water 2487). The amount of
released lactone was calculated using a calibration curve obtained from known
concentrations of QPA lactone solutions in acetonitrile.

3.2.7. In vitro drug release study
In vitro drug release from polyQPA-mPEG750 micelles was examined by
challenging the micellar solution with sodium dithionite to reduce QPA groups after
loading PTX in micelles as a model drug. Based on a HPLC measurement performed
prior to drug release study, it was shown that one milligram of polyQPA-mPEG750
micelle contained 177.4 µg of PTX. One hundred microliter of 0.5% of PTX loaded
polymer micelles containing 88.7 µg of PTX was used for the study. Forty milliliters of
PBS including sodium salicylate at a concentration of 0.8 M were used for redoxtriggered drug release. After placing polyQPA-mPEG750 micelle in a dialysis membrane
of MWCO 1,000 Da (Spectrum Laboratories), the dialysis membrane was immersed in
drug release media equilibrated at 37 °C and the release media were continuously
agitated by magnetic stirring. For redox-triggered PTX release from polyQPA-mPEG750
micelles, an amount of sodium dithionite to achieve a final concentration of 29 mM was
added in the medium. In addition, the solution consisting of PTX (88.7 µg) was utilized
as a control. Samples were withdrawn from the release medium at predetermined time
points and were analyzed by HPLC.
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3.2.8. Cell culture
Human breast tumor T47D and MDA-MB-231 cells lines were purchased from
ATCC, Manassas, VA and used in this work. These cell lines were cultured in
DMEM/F12 medium containing 2.5 mM L-glutamine (Mediatech), supplemented with
fetal bovine serum (FBS, 10% v/v final concentration, Hyclone), penicillin G (sodium
salt, 50 units mL-1) and streptomycin sulfate (50 µg mL-1) (BioWhittaker). Exponentially
grown cells were plated at the density of 30,000 cells per well into 96-well plates in a
volume of 100 µL culture media and incubated at 37 °C in a humidified environment
(95% air, 5% CO2) as previously reported 61.
3.2.9. In vitro antitumor activity of polyQPA-mPEG750 micelles
The cytotoxicity of PTX formulated in polyQPA-mPEG750 was evaluated in
human breast tumor T47D and MDA-MB-231 cells lines, in comparison to free PTX.
Briefly, after seeing in 96-well plates followed by overnight attachment, the cells were
treated by PTX-loaded micelles with varied concentrations. Free PTX, at concentrations
equivalent to the PTX incorporated in micelles, was also added into cells. After treatment
for 24 h, the cells were further incubated and cell viability was determined by a
sulforhodamine B (SRB) method 62. Optical density (OD) was measured at 490 nm with
background absorption at 630 nm. Data were normalized to the untreated control and
presented as ‘% of control,’ using the formula.
Cell viability (% of Control) = (ODtreated/ODcontrol) × 100
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3.2.10. Statistical analysis
Experimental measurements were triplicated for each sample. The results are
presented as mean ± standard deviation. The statistical analysis of experimental data
utilized the student’s t-test and statistical significance was considered for P-values < 0.05.

3.3. RESULTS
3.3.1. Synthesis and Characterization of polyQPA-mPEG750
PolyQPA-mPEG750, designed for redox-responsive polymer micelles, were
synthesized as illustrated. After synthesis of hydrophobic block, polyQPA, as presented
in Scheme 3.1, the following reaction with an additional amount of adipoyl chloride
provided reactive end groups in polyQPA. The reactive polyQPA underwent end-capping
with mPEG of molecular weights 750 to achieve redox-sensitive block copolymers. The
1

H-NMR spectrum of polyQPA-mPEG750 in Figure 3.1. showed the peaks of mPEG at δ

= 3.64 ppm (-CH2CH2O-) and 3.37 ppm (CH3O-) in CDCl3. Moreover, three methyl
(CH3-) protons of quinone was presented at 1.95-1.96 and 2.12 ppm. Resultant polyQPAmPEG750 was obtained as a yellow solid exhibited good water solubility.
Number average molecular weight (Mn) and polydispersity (PDI) of the redoxsensitive block copolymer were determined to be 3640 and 1.65, respectively, by GPC.
Clear shift in the molar mass distribution to shorter retention times was observed. Before
the end-capping of the PEG at the end of the hydrophobic group, the molecular weight of
hydrophobic polymer was calculated as 2482 with PDI of 1.37 by GPC measurements.
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Figure 3.1. 1H-NMR spectrum of polyQPA-mPEG750 in CDCl3. The letters denote peak
assignments in 1H-NMR spectra.

3.3.2. Micelle formulation
The ability of polyQPA-mPEG750 to self-assemble into micelles was examined by
a CMC measurement. The CMC of polyQPA-mPEG750 was determined by a method
based on hydrophobic dye solubilization as shown in Figure 3.2.. At a concentration
below CMC, amphiphilic polyQPA-mPEG750 was not able to increase DPH solubility,
resulting in inadequate UV absorbance. A dramatic increase in UV absorbance was
observed at a polymer concentration greater than CMC. The CMC was determined by a
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graphical extrapolation of two phases of UV absorbance changes and reading out the
polymer concentration at which they crossed over. The CMC of polyQPA-mPEG750 in
PBS was found to be 0.039% w/v (0.39 mg mL-1, 0.107 mM) at 25 °C.

Figure 3.2. (A) Determination of the critical micelle concentration of polyQPA-mPEG750
using DPH. The difference in the absorbance intensities of DPH at wavelengths of 377
and 391 nm was plotted as a function of polyQPA-mPEG750 concentration. CMC was
determined by reading out the point, A, at which two extrapolated lines were crossed. (B)
A representative particle size distribution of drug-free micelles was obtained by DLS
measurement at 25 ± 1 °C. Determined average particles size was 27.50 nm with a PI of
0.064.
Both PTX-free and PTX-loaded polymeric micelles were prepared by a solid
dispersion technique which was also applied to prepare for PTX-loaded polymer micelles
from monomethoxy poly(ethylene glycol)-block-poly(D,L-lactide) (mPEG-PDLLA)93.
During the process of micelle preparation, the amount of residual acetonitrile, the solvent
to dissolve polyQPA-mPEG750 and PTX, was under the detection limit by 1H NMR
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spectroscopy measurements after vacuum drying. A simple hydration of the mixture of
polyQPA-mPEG750 and PTX with PBS enabled to produce micelle formulations.
The mean diameter of resultant PTX-free micelles was determined to be 27.50 nm
with a PI of 0.064 at 25 ± 1 °C by DLS as presented in Figure 3.2. However, the average
size of PTX-loaded micelles was 79.92 nm, which was noticeably larger than that of
PTX-free micelles. The amount of PTX loaded in 1 mg of polyQPA-mPEG750 micelles
was found to be 177.4 µg indicating a loading content of 17.74% while drug loading
efficiency was found to be 82.5%.

3.3.3. Redox-responsive polymer degradation
PolyQPA-mPEG750 was examined for its reduction in the presence of a redox chemical.
Since we are interested in redox-triggered drug release from polyQPA-mPEG750 micelles,
we primarily focused on the characterization of dimensional changes occurring to the
micelles in the presence of a redox chemical. This would be eventually translated into
drug release. As shown in Figure 3.3., the micellar size based on averaged volume has
significantly changed upon the addition of a redox chemical, sodium dithionite. The size
of polyQPA-mPEG750 micelles rapidly increased from 28 nm to 64 nm within 5 min after
the addition of sodium dithionite while no noticeable change in micellar size was
observed from the control without sodium dithionite. The average size of micelles further
increased to reach 3338 nm at a time point of 30 min. The increase in polyQPA-mPEG750
micelle size in the presence of sodium dithionite is attributed to the solubility reversal
occurred to the hydrophobic polyQPA core which would become hydrophilic after the
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removal of hydrophobic pendant QPA groups via intramolecular cyclization. In addition,
PI of the NPs increased over three hours indicating more heterogeneous particle
population.

Figure 3.3. Redox-triggered particle size change in polyQPA-mPEG750 micelles was
monitored by dynamic light scattering measurements in the presence or absence of
sodium dithionite.

The effect of sodium dithionite on polyQPA-mPEG750 was directly examined by
NMR measurement. Figure 3.4.(A) has shown reduction mechanism of QPA switches in
polyQPA-mPEG750 copolymer with sodium dithionite and the letters in Figure 3.4.(A)
indicate peak assignments in 1H-NMR spectra. After dissolving polyQPA-mPEG750 in a
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co-solvent of acetone-d6 : D2O (2:1, v/v) to warrant the solubility of both lactone and
copolymer, NMR spectra were periodically recorded with or without sodium dithionite
shown in Figure 3.4 (B 1-3).
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Figure 3.4. (A) Reduction mechanism of redox-switches in polyQPA-mPEG750
copolymer using sodium dithionite and release of QPA lactone. The letters denote peak
assignments in 1H-NMR spectra. (B) 1H-NMR spectra (400 MHz) of polyQPA-mPEG750
were recorded in acetone-d6 and deuterium oxide (1.5%, 1:2, w/v) before (B-1) and after
(B-2, 30 min, and B-3, 3 h) an addition of sodium dithionite at a concentration of 29 mM.
The NMR spectrum of lactone (B-4) is also measured for comparison.

Figure 3.4. (B) also includes the NMR spectrum of QPA lactone as control to compare
with (Figure 3.4. (B-4)). When sodium dithionite was added into micelle solution, all
proton peaks in NMR spectra (Figure 3.4. (B)) were slightly shifted (< 0.25 ppm)
compared to the one recorded before adding sodium dithionite. This result is because of
ionic strength changes in the NMR sample solution and the similar result were presented
in the reported publication
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. The addition of sodium dithionite also resulted in the

appearance of proton peaks attributed to six protons of methyl groups in QPA lactone at δ
= 1.33 ppm. In addition, 30 min after the initiation of reduction, the proton peak from
QPA pendant groups in polyQPA-mPEG750 (-COCH2C-) has shifted from δ = 2.75 to
2.51 ppm, indicating the QPA lactone formation by intramolecular cyclization.

3.3.4. Redox-triggered QPA lactone release from polyQPA-mPEG750 micelles
In order to quantitatively analyze QPA reduction in polyQPA-mPEG750 micelles,
the amount of QPA lactone released from polyQPA-mPEG750 was measured as a function
of time in the presence and absence of the redox agent. As shown in Figure 3.5, there was
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no noticeable QPA lactone release from the control which did not contain the redox
agent. QPA reduction in polyQPA-mPEG750 micelles was rapid enough to release
60.04% and 67.04% of QPA groups at polymer concentrations of 0.01 and 0.50%,
respectively in 30 min after the initiation of the reduction. Cumulative QPA lactone
release reached to 85.30% and 72.62% within 24 hours at polymer concentrations of
0.01% and 0.50%, respectively. At 48 hours after the addition of sodium dithionite, QPA
lactone generated from 0.01% of polyQPA-mPEG was 88.09% which reveals no
statistically significant differences (two-tailed t-test, p > 0.05) even after 48 hours of
incubation.
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Figure 3.5. Redox-triggered QPA lactone release from polyQPA-mPEG750 solution in
PBS buffer (pH 7.4) at 37 °C. Cumulative QPA lactone release from polyQPA-mPEG750
at concentrations of 0.50% (A) and 0.01% (B) was plotted as a function of time after an
addition of each reducing agent, sodium dithionite (●) or DT-diaphorae/β-NADH (∆).
The control (×) was copolymers without those reducing agents.

In addition, polyQPA-mPEG750 micelles were also able to release QPA lactone
via redox enzyme-mediated bioreduction. Indeed, DT-diaphorase could trigger QPA
reduction to result in spontaneous QPA lactone release from hydrophobic cores of
polyQPA-mPEG750 micelles. DT-diaphorase-mediated QPA reduction, however, was
dependent on polymer concentration. Cumulative amounts of QPA lactone released by 5
units of DT-diaphorase in the presence of 2 mM of a cofactor β-NADH at 37 °C reached
to 61.84% and 20.87% at polymer concentrations of 0.01% (Figure 3.5. (B)), a
concentration below CMC, and 0.50% (Figure 3.5. (A)), a concentration above CMC,
80

respectively. This result indicated that the supramolecular structure of polyQPA-mPEG750
assembly could

affect the efficiency of DT-diaphorase-mediated QPA reduction.

3.3.5. In vitro PTX release from polyQPA-mPEG750 micelles
In vitro PTX release from polyQPA-mPEG750 micelles, examined by a dialysis
method in the presence of sodium dithionite, demonstrated that QPA reduction in
polyQPA-mPEG750 micelles could trigger the release of incorporated PTX. As seen in
Figure 3.6, polyQPA-mPEG750 micelles have released only 17.08% of loaded PTX over a
period of 36 h in the absence of sodium dithionite. An addition of the redox agent into the
polyQPA-mPEG750 micellar solution has dramatically increased the release of PTX
resulting in a significant increase in cumulative release of PTX from 18.20% to 52.53%
between time points 3 h and 12 h, respectively (p < 0.05). The cumulative PTX release
has further increased to 65.73% at 36 h after triggering QPA reduction. Triggered PTX
release from polyQPA-mPEG750 micelles was comparable to the PTX release profile
from pure PTX solution.
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Figure 3.6. Redox-triggered PTX release from polyQPA-mPEG750 micelles in the
presence (■) and absence (○) of sodium dithionite (29 mM) at 37 °C. An addition of PTX
solution with sodium dithionite was used as the control to compare with (×).

3.3.6. In vitro antitumor activity of polyQPA-mPEG750 micelles
Concentration-dependent cell cytotoxicity studies were performed to determine
the effects of PTX-loaded polyQPA-mPEG micelles on the proliferation/viability of
human breast tumor cells. As shown in Figure 3.7. (A), at a drug dose of 0.1 µM, cell
viabilities of 20% and 24% were observed for MDA-MB-231 cell line following 24 h of
incubation with free PTX and PTX-loaded micelles, respectively. The cell experiment for
T47D cell line in Figure 3.7. (B) also showed similar cell viability, in which 22% and
82

26% of cell viability were observed for plain drug, PTX loaded micelles, respectively.
The IC50 (i.e., inhibitory concentration to produce 50% cell death) of PTX-loaded
micelles, were 217.6 µM and 277.0 µM for MDA-MB-231 and T47D cell lines,
respectively, while those of free PTX were 323.3 µM and 296.1 µM.

Figure 3.7. Effects of paclitaxel loaded micelles on human breast tumor cell
proliferation/viability determined by SRB method: (A) MDA-MB-231 cells (B) T47D
cells. Exponentially grown T47D and MDA-MB-231 cells were exposed to the different
concentration of PTX-loaded micelles (•) and PTX (×) for 24 h under normoxic condition
(95% air : 5% CO2). Data shown are average standard deviation (n=3).

3.4. DISCUSSION
We have previously reported QPA-based redox-responsive polymeric NPs
enabling drug release under a simulated redox state. In this study, we developed a redoxresponsive amphiphilic block copolymer containing QPA triggers, polyQPA-mPEG750,
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which is able to self-assemble into micelles, load a hydrophobic drug, and release the
drug in response to a redox change. Redox-responsive copolymers were synthesized in a
two-step reaction. In the first step in Scheme 3.1, hydrophobic polyQPA block was
synthesized by esterification between QPA-serinol and adipoyl chloride as previously
reported.82,90 The esterification was occurred by the reaction between two hydroxyls in
QPA-serinol and reactive two acyl chloride groups in adipoyl chloride. For the following
end-capping of polyQPA with mPEG, both terminal functional groups needed to be
identically reactive towards the hydroxyl group of mPEG. Since terminal functional
groups of polyQPA could be either hydroxyl or acyl chloride, an additional amount of
adipoyl chloride was added to secure reactive acyl chloride groups at both ends. The
activated polyQPA was reacted with dried mPEG750 to obtain redox-sensitive amphiphilic
polyQPA-mPEG. Based on molecular weight analysis, molecular weights of polyQPAmPEG750 and polyQPA, 3640 and 2482 respectively, may indicate that polyQPAmPEG750 possesses mixture of tri-block copolymer and diblock copolymer with
consideration of mPEG molecular weight 750.
Self-assembling of polyQPA-mPEG750 into micelles was supported by
demonstration of CMC. The CMC of polyQPA-mPEG750 was 0.039% w/v, which is
lower than commercially available amphiphilic tri-block copolymers, poly(ethylene
glycol)-poly(propylene glycol)-poly(ethylene glycol) (Pluronic®). CMCs of Pluronic®
polymers range from 0.6% to 4%
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. Partiucularly, Pluronic® L64 (MW of 3400 and a

PEG content of 40%), which has molecular characteristics similar to polyQPA-mPEG750
(MW of 3600 and a PEG content of 41%), has a CMC of 4% w/v. It is well established
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that self-assembling of amphiphilic block copolymers into micelles is primarily
dependent on the nature and length of hydrophobic block.97-98 The determined CMC of
polyQPA-mPEG750 lower than that of Pluronic® L64 may indicate that polyQPA is more
hydrophobic than poly(propylene glycol).
Particle size of polyQPA-mPEG750 measured by dynamic light scattering has
shown that micellar sizes of drug-free and drug-loaded micelles were in a range between
20 nm and 100 nm. It should also be noted that the size of PTX-free polyQPA-mPEG750
micelles was smaller than that of drug-loaded micelles. It has been reported that loading a
hydrophobic drug in the core of polymer micelle often expands micelles and increases
micelle size.99 PolyQPA-mPEG750 micelles, both drug-free and drug-loaded, were smaller
than other nanocarriers with QPA redox switches such as liposome 34 and nanoparticles 90
of which particles sizes were ~100 nm and 249.8 nm, respectively. It has been suggested
that drug carriers within a size range between 10 nm and 200 nm would avoid
reticuloendothelial system (RES)-mediated particle clearance, which would be beneficial
for a prolonged systemic circulation.100 Considering particle size and protective PEG
brushes on surface, polyQPA-mPEG750 micelles would be useful for drug delivery
applications.
Generally, hydrophobic drug loading into micellar structures is affected by
molecular interactions between a drug and hydrophobic micelle core and steric factors
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. In this study paclitaxel was utilized as a model hydrophobic drug to assess the

application of prepared micelles to drug delivery. Our previous publication reported that
the Flory-Huggins interaction parameter (χ) between polyQPA and PTX was estimated to
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be 0.031 by solubility parameters calculated from the Molecular Dynamic simulations,
suggesting a good miscibility

90

. Indeed, a relatively high PTX loading efficiency of

82.5% as well as a drug loading content of 18% was achieved with polyQPA-mPEG750
micelles. Such favorable drug loading might cause more than two-fold increase in micelle
size from 27.50 nm to 79.92 nm, which is comparable to other biodegradable polymer
micelles incorporated with hydrophobic drugs 100.

Scheme 3.2. Schematic illustration of drug release from redox-responsive polyQPAmPEG750 micelles upon redox-triggered QPA reduction.

For a successful application of polyQPA-mPEG750 micelles as a drug delivery
system, redox-triggered dissembling of the micelles and subsequent drug release are very
important. Therefore, polyQPA-mPEG750 micelles were tested for their redox-triggered
dimensional changes and drug release. As illustrated in Scheme 3.2, drug-incorporated
micelles are stable in the absence of sodium dithionite. However, in the presence of
sodium dithionite these micelles are expected to expand upon initiation of QPA reduction
in the hydrophobic core thereby releasing the entrapped drug. It has been previously
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reported that hydrophobic polyQPA undergoes a solubility reversal by exposing free
amine groups after QPA lactone release via spontaneous intra molecular cyclization in
the presence of the redox trigger 82, 90. With protonation of exposed free amine groups in
pH 7.4, the size of polymeric micelles should increase by swelling due to the repulsive
ionic interactions introduced after the removal of QPA lactone. As expected, polyQPAmPEG750 micelles started to rapidly swell to reach 3338 nm (PI~1.0) within 30 min after
the initiation of QPA reduction, indicating that micelle cores were swollen because of
polymer hydration induced by the solubility reversal occurred in the polyQPA block.
Swollen micelles with loosely interwoven polymer chains in the core would be able to
facilitate the release of incorporated PTX. This unique property of redox-triggered
dimensional changes in polyQPA-mPEG750 micelles may be useful for targeted drug
delivery to the tissues with altered redox state such as tumors.
Redox-triggered structural change in polyQPA-mPEG750 was also examined by
NMR measurements to mechanistically correlate the effect of the redox trigger on the
molecular property changes in the polymer which could be related to drug release.
Yellow polyQPA-mPEG750 solution became colorless implying that QPA groups were
reduced to hydroquinone. The NMR spectrum recorded at 30 min after the addition of
sodium dithionite showed characteristic proton peaks of QPA lactone, reduced polyQPAmPEG750 backbone and partially reduced quinone (Figure 3.4.(B-2)). In particular, the
characteristic QPA lactone peaks (Figure 3.4. (B-3)) recorded in 3 h appeared after
polymer reduction match with the peaks in the NMR spectrum measured with QPA
lactone control (Figure 3.4. (B-4)), which indicates successful QPA group reduction.
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Combining the experimental results of redox-triggered dimensional changes in micelles
and structural changes in polyQPA-mPEG750, the redox-responsive polyQPA-mPEG750
micelles could be swollen by redox-triggered QPA lactone release within 30 min as
presented in Scheme 3.2..
Quantitative analysis of lactone was assessed to get further informative insight
into the underlying physical and chemical reduction processes of redox-responsive
micelles, which can be eventually translated into drug release. The QPA lactone release
profile in Figure 3.5. has clearly demonstrated that most QPA in the core of polyQPAmPEG750 micelles was as a lactone form in the presence of sodium dithionite regardless
of polymer concentration. This result is consistent with QPA reduction on polyQPAmPEG750 characterized by NMR measurements (Figure 3.4). It also worth mentioning
that PEG block attachment did not affect QPA lactone release from polyQPA. QPA
lactone release from polyQPA-mPEG750 micelles was similar to that from polyQPA NPs.
82, 90

Considering the degradation of polyQPA-mPEG750 backbone chain, a change of its

hydrophobicity due to carboxylic acid ends liberated by cleavage of their ester bonds will
facilitate the reduction of QPA group which leads to an immediate QPA lactone release
(Figure 3.5.). As shown in Figure 3.5., enzymatic reduction of polyQPA-mPEG750 was
noticeably different from that with sodium dithionite. A redox enzyme often upregulated
in tumors, DT-diaphorase, could release QPA lactone from polyQPA-mPEG750.
However, the enzymatic QPA reduction on polyQPA-mPEG750 was clearly affected by
polymer concentration, indicating that a steric factor is involved in DT-diaphorasemediated QPA reduction from polyQPA-mPEG750 as seen in Figure 3.5. DT-diaphorase
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was able to reduce QPA on polyQPA-mPEG750 when the polymer concentration, 0.01%,
was below CMC, 0.039% w/v. When polymer concentration, 0.5%, increased to above
CMC, however, DT-diaphorase was not effective in reducing QPA groups. This result
indicates that the enzyme had a limited access to QPA groups on polyQPA-mPEG750
when the polymer assembled into micelles. The QPA groups in the hydrophobic block
would be hidden inside the micelle core and also masked by the PEG layer on micelle
surface. This explanation may be valid based on the reported work with N-(2hydroxypropyl)methacrylamide micelles containing hydrophobic oligopeptide side
chains. Ulbrich et al. demonstrated that the penetration of enzyme into micelle core was
impeded by structural hindrance, thereby preventing the effective enzyme binding to
substrate
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. However, hydrophilic PEG blocks might contribute to increasing water

solubility of polyQPA and facilitating the binding between DT-diaphorase and QPA
groups on polyQPA-mPEG750 under a polymer concentration below CMC since most
polymer molecules exist as a unimer instead of being associated. The collective results
also indicated the process of QPA lactonization plays an important role during the
destabilization process of micelle, thereby enabling the release of loaded drug.
In vitro PTX release kinetics, indeed, was well correlated with QPA reduction and
QPA lactone release previously discussed. PTX release from polyQPA-mPEG750 micelles
in the presence of sodium dithionite was significantly (p < 0.01) greater than drug release
in the absence of the redox chemical (Figure 3.6.). PTX release from the micelles was
even very similar to that from the control, PTX solution itself (two-tailed t-test, p > 0.2)
assuring that most of incorporated drug was released from the polyQPA-mPEG750
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micelles over a period of experiment time in the presence of the redox chemical. Overall
a cumulative PTX release of greater than 80% was comparable to that reported from our
previous work with polyQPA NPs 90. Based on the results presented in Figures 3.5. and
3.6., PTX-loaded redox-responsive polyQPA-mPEG750 micelles were stable in aqueous
environments and able to release the incorporated PTX by redox-triggered QPA
reduction which disrupted micelle structure.
The antitumor activity of polyQPA-mPEG750 micelles was studied in human
breast tumor T47D and MDA-MB-231 cells to determine cancer cell mediated drug
release. Free PTX was used as positive controls for the study. As shown in Figure 3.7, a
concentration-dependent cell-killing effect was shown for PTX-loaded micelles. These
PTX-loaded micelles inhibited cell proliferation and viability to the comparable extent as
that observed in the presence of PTX. This result may indicate an increased cellular
uptake of PTX-loaded polyQPA-mPEG micelles owing to hydrophilic PEG chain on the
surface and release all incorporated PTX from micelles to limit tumor cell growth.
Indeed, the similar result was presented in the reported publication.103 When doxorubicin
was delivered by poly(DL-lactic-co-glycolic acid)-mPEG2000 micelles exhibited greater
uptake by HepG2 cells, compared to free drug because there is no specific affinity
between the outer PEG chains of micelles and negatively charged plasma membrane of
the cells.103 It seemed that the PEG-grafted redox-responsive polymeric micelle would
resist opsonization and phagocytic clearance and enable to release the loaded drug to
limit tumor cell growth. The antitumor activity of these polyQPA-mPEG750 micelles may
be boostered by decorating the hydroxyl end of redox-responsive micelle, polyQPA90

mPEG750, with a targeting ligand such as antibody fragment and folic acid which improve
its specificity for drug delivery through active pathway.104 These polyQPA-mPEG750
micelles have integrated features including relatively high drug loading, micellar
stability, redox-triggered dimensional change, and redox-mediated drug release, which
collectively provide a useful delivery platform for cytotoxic cancer drugs.

3.5. CONCLUSIONS
A novel redox-responsive amphiphilic polymer comprising QPA redox switches
and hydrophilic mPEG, polyQPA-mPEG750, was successfully synthesized and
characterized. Coupling of mPEG to hydrophobic polyQPA provided polyQPA-mPEG750
with improvement of water-solubility as well as self-assembling capability into micelles.
Furthermore, incorporation of QPA redox switches into amphiphilic polymer led to
unique micelles which enable to rapidly undergo dimensional changes upon QPA
reduction and thus release incorporated drug in a redox-triggered manner. PTX-loaded
polyQPA-mPEG750 micelles, indeed, has demonstrated a redox-responsive drug release.
Redox-responsive polyQPA-mPEG750 micelles may be useful as a drug delivery system
targeting tumor microenvironments which frequently show altered redox state and/or
redox enzyme upregulation.
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CHAPTER 4
NITROREDUCTASE-TRIGGERED ACTIVATION OF A NOVEL CAGED
FLUORESCENT PROBE OBTAINED FROM METHYLENE BLUE
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ABSTRACT

A novel NIR fluorescent probe, p-nitrobenzyl 3,7-bis(dimethylamino)-10Hphenothiazine-10-carboxylate was developed from methylene blue for the selective
imaging and therapy. Conjugating methylene blue with a p-nitrobenzyl moiety redox
switch enables it to quench electron transfer within the molecules, thereby leading to
improvements in achievable target-to-background auto-fluorescence ratio. Moreover the
redox trigger caged probe is readily activated by nitroreductase-catalyzed 1,6elimination, resulting in the release of active methylene blue fluorophore. This
fluorescent probe exhibits neither significant NIR fluorescence intensity nor absorbance
between 500 nm to 800 nm. However, it was activated to release the strong fluorescence
(λmax = 680 nm) with the excitation at 580 nm upon nitroreductase-mediated two-electron
reduction of the redox switch. In addition, the fluorescence emission was induced by
incubation with live Escherichia coli bacteria. It was demonstrated that the NIR
fluorescent probe generated singlet oxygen after nitroreductase mediated reduction with a
laser irradiation at a wavelength of 634 nm. The redox trigger caged NIR fluorescent
probe would be a suitable imaging sensor to detect bacteria expressing NTR. In addition,
p-NBMB also possesses potential as an MB prodrug which can be applied for the
treatment of various diseases.
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4.1. INTRODUCTION
Nitroreductase (NTR), a flavin mononucleotide (FMN) cofactor dependent
protein expressed in Escherichia coli (E. coli), catalyzes reduction of a nitro group to
hydroxylamine, which is subsequently converted to an amine in the presence of
nicotinamide adenine dinucleotide phosphate (NAD(P)H) as a cofactor.105 The large
electronic change resulting from conversion of the electron-withdrawing nitro group to
the electron-donating hydroxylamino group provides a selective ‘switch’ mechanism for
the activation of an inert compound which leads to the subsequent release of the active
agent. Based on this switch mechanism, various prodrug or activatable imaging probes
have been designed with nitro groups as substrates to be triggered upon reduction by
NTR.106 The dicoumarin carbonate-based latent fluorophore was devised for the
application in imaging to improve selectivity for NTR and aqueous solubility.106b
Furthermore, NTR was employed in development of gene-directed enzyme prodrug
cancer therapies (GDEPT), antibody-directed enzyme prodrug therapy (ADEPT) and
drug screening as exemplified with 2,4-dinitrobenzamide (CB1954).107 The basis of
CB1954 activation has been fully elucidated and the molecule has advanced into clinical
trials.35
Despite the previous extensive investigation about the use of nitrobenzyl redox
switches for NTR activatable materials, these switches have not been applied for the
development of bifunctional compounds, which can serve as a tool for selective imaging
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and therapy.2-4 To design NTR activatable agents with combined imaging and therapeutic
function, the selection of an appropriate reporter is of great importance. Among various
reporters, fluorophores with emission in the far red and near-infrared (NIR), in the range
of 600-1000 nm, are widely utilized in relevant research settings to overcome the
limitation of poor tissue penetration owing to the interference from background autofluorescence from biomolecules.8-9 In addition, NIR fluorophores offer several additional
advantages over conventional imaging agents including high resolution, sensitivity and
non-invasiveness.108 In particular, methylene blue (MB) has been recognized as a
sensible starting point for the development of a better NIR fluorophore given MB’s
strong absorption of broadband red light (550-700 nm, maximum at 664 nm), a
wavelength at which absorption and autofluorescence are minimal.109 Moreover, MB has
been applied for clinical therapeutic purposes including treating methemoglobinemia,
Barrett’s

esophagus,

and

cervical

cancer.110
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mononucleotide (FMN) cofactor dependent protein expressed in Escherichia coli (E.
coli), catalyzes reduction of a nitro group to hydroxylamine, which is subsequently
converted to an amine in the presence of nicotinamide adenine dinucleotide phosphate
(NAD(P)H) as a cofactor.105 The large electronic change resulting from conversion of the
electron-withdrawing nitro group to the electron-donating hydroxylamino group provides
a selective ‘switch’ mechanism for the activation of an inert compound which leads to the
subsequent release of the active agent. Based on this switch mechanism, various prodrug
or activatable imaging probes have been designed with nitro groups as substrates to be
triggered upon reduction by NTR.106 The dicoumarin carbonate-based latent fluorophore
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was devised for the application in imaging to improve selectivity for NTR and aqueous
solubility.106b Furthermore, NTR was employed in development of gene-directed enzyme
prodrug cancer therapies (GDEPT), antibody-directed enzyme prodrug therapy (ADEPT)
and drug screening as exemplified with 2,4-dinitrobenzamide (CB1954).107 The basis of
CB1954 activation has been fully elucidated and the molecule has advanced into clinical
trials.35
Despite the previous extensive investigation about the use of nitrobenzyl redox
switches for NTR activatable materials, these switches have not been applied for the
development of bifunctional compounds, which can serve as a tool for selective imaging
and therapy.2-4 To design NTR activatable agents with combined imaging and therapeutic
function, the selection of an appropriate reporter is of great importance. Among various
reporters, fluorophores with emission in the far red and near-infrared (NIR), in the range
of 600-1000 nm, are widely utilized in relevant research settings to overcome the
limitation of poor tissue penetration owing to the interference from background autofluorescence from biomolecules.8-9 In addition, NIR fluorophores offer several additional
advantages over conventional imaging agents including high resolution, sensitivity and
non-invasiveness.108 In particular, methylene blue (MB) has been recognized as a
sensible starting point for the development of a better NIR fluorophore given MB’s
strong absorption of broadband red light (550-700 nm, maximum at 664 nm), a
wavelength at which absorption and autofluorescence are minimal.109 Moreover, MB has
been applied for clinical therapeutic purposes including treating methemoglobinemia,
Barrett’s esophagus, and cervical cancer.110 MB is also known to be photodynamically
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Scheme 4.1. Mechanism of switching on the fluorescence probe, p-NBMB, upon
reduction of a p-nitrobenzyl moiety after nitroreductase-mediated activation.
active so that it can inactivate viruses, destroy bacteria, and inhibit cancer cell growth.109b,
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Given its advantageous properties, MB may be an ideal compound to use in design of

an NTR-switchable probe with both imaging and therapeutic capability. In this study, we
describe a novel NIR fluorescent probe, p-nitrobenzyl 3,7-bis(dimethylamino)-10Hphenothiazine-10-carboxylate (p-NBMB) which can be triggered by NTR. To obtain a
MB-based latent fluorescent probe, which is activatable, a p-nitrobenzyl moiety as an
NTR switch was conjugated to cage MB at the nitrogen of the phenothiazine ring through
a carbamate bond, thereby quenching electron transfer within the molecule (Scheme
4.1.). This ultimately leads to improvements in achievable target-to-background autofluorescence ratios. In the presence of NTR, the resultant caged fluorescent probe is
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intended to be turned back on undergoing reduction of the aryl nitro group. Subsequently,
the benzyl moiety will be removed by a rapid 1,6-elimination (Scheme 4.1.). We
primarily assessed the feasibility of whether a novel p-NBMB can be developed into an
NTR selective activatable agent. Additionally, a potential therapeutic application of the
compound in photodynamic therapy was also addressed.

4.2. EXPERIMENTAL
4.2.1. Materials
4-Nitrobenzyl chloroformate, nitroreductase from Escherichia coli (E. coli),
human DT-diaphorase, β-nicotinamide adenine dinucleotide, reduced dipotassium salt
hydrate (NAD(P)H), and p-nitrosodimethylaniline were purchased from Sigma-Aldrich
(Saint Louis, MO). Certified grade methylene blue (MB) was obtained from Acros
Organics (Pittsburgh, PA). All other chemicals were purchased from Fisher Scientific
(Pittsburgh, PA) and used as received.

4.2.2. Synthesis of p-nitrobenzyl 3,7-bis(dimethylamino)-10H-phenothiazine-10carboxylate (p-NBMB)
Methylene blue (MB, 373.9 mg, 1 mmol) was dissolved in 10 mL of deionized
water.

Toluene (40 mL), sodium bicarbonate (292.4 mg, 3.48 mmol) and sodium

dithionate (496.2 mg, 2.85 mmol) were added to the solution of MB, stirring at 50 °C.
When the mixture turned to yellow, after 30 min, the toluene phase containing leuco-MB
was transferred dropwise over 60 min into a solution of p-nitrobenzyl chloroformate
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dissolved in 40 mL of toluene, maintained in an ice bath. After overnight reaction at
room temperature, the mixture was collected after washing with water three times. The
obtained organic phase was evaporated under reduced pressure and then was precipitated
into cold methanol. The precipitates were purified by recrystallization from acetonitrile
yielding orange solid powder: yield (52.25 mg, 11.24%): 1H NMR (400 MHz, CDCl3) δ
8.21 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.6 Hz, 2H), 6.70 (d, J =
2.5 Hz, 2H), 6.64 (dd, J = 8.9, 2.3 Hz, 2H), 5.32 (s, 2H), 2.96 (s, 12H), 1.57 (s, 2H).
Found C, 61.88; H, 5.10; N, 12.06. Calcd for C24H24N4O4S: C, 62.05; H, 5.21; N, 12.06

4.2.3. Spectroscopic assessment
All spectroscopic measurements were performed in 10 mM phosphate buffered
saline solution (PBS, pH 7.4, 1% DMSO). For the spectrometer measurements, a quartz
cuvette with 1 cm path length was used to hold each sample. The absorbance of the
solution was measured using a Genesys 6 spectrophotometer (Thermo Fisher Scientific,
Inc., USA). Fluorescence spectra were acquired both using a PerkinElmer LS55
fluorescence spectrometer (Massachusetts) and an inverted microscope setup. A
wavelength of 580 nm was chosen as the excitation source and fluorescence was detected
in a wavelength range between 640 and 800 nm. The heterogeneity of the sample was
probed using an inverted Nikon TE200U microscope with a 10x objective (NA = 1.4).
The 514.5 nm laser line of an Ar+ ion laser (~500 µW) was used to excite the sample,
which was deposited on plasma cleaned glass coverslips. An Acton SP2500 spectrograph
with a 150 grooves mm-1 grating was employed to disperse the emission and a Princeton
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Instruments ProEM 1024 EMCCD camera was used to record the fluorescence emission
between 620 and 800 nm.

4.2.4. Spectral analysis of p-NBMB
The solutions of p-NBMB (1 µM) in deionized water (1% DMSO) were prepared
to assess spectral analysis of p-NBMB. The fluorescence and absorbance of p-NBMB
was evaluated using a UV-Visible spectrophotometer and fluorescence spectrometer,
respectively, along with MB (1 µM) as a reference.

4.2.5. Nitroreductase activity assay
p-NBMB was dissolved in DMSO to obtain a stock solution of 10 mM and the
stock solution was diluted to achieve concentrations ranging from 1 µM to 100 µM.
Nitroreductase was mixed to dilute p-NBMB solution with an enzyme assay buffer (1
mM NAD(P)H, PBS) containing 1% DMSO to achieve final enzyme concentrations of 1
unit mL-1 and 2 units mL-1. All prepared samples were incubated at 37 °C. Fluorescence
spectra were measured with/without nitroreductase, changing the concentration of
imaging probe and enzyme. Fluorescent images were obtained using IVIS Spectrum
(Caliper Life Sciences, Perkin Elmer). Excitation light of 640 +/- 17 nm was used, and
fluorescence emission was collected at 800 +/- 10 nm (Auto exposure, F stop 2, small
binning). Mean fluorescence radiant efficiency was obtained for each well using Living
Image Software (Caliper Life Sciences).
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4.2.6. E. coli assay
E. coli XL1-Blue were grown in 3 mL of terrific broth without antibiotic
overnight at 37 °C. At the end of the incubation, the bacteria were centrifuged at 2000xg
for 10 minutes at 4 °C. The bacterial pellet was resuspended in 1 mL of PBS containing
1% DMSO. To investigate the fluorescent response of p-NBMB to intact E. coli, bacteria
(approximately 109 CFU mL-1) were added to each well of a black 96 well plate.
Afterward, p-NBMB was added to a final concentration of 1 – 50 µM to each well of the
96 well plate. In addition, fluorescence response of p-NBMB to serial number of E. coli
was examined. The bacterial suspension (approximately 109 CFU mL-1) was serially
diluted in PBS containing 1% DMSO in the following concentrations: undiluted, 1/10,
1/102, and 1/103. 100 µL of PBS containing 1% DMSO, undiluted, and diluted bacterial
suspension were transferred to a black 96 well plate containing 50 µM of p-NBMB and
incubated at 37 °C for 4 hours. After the treatment, these well plates were incubated at 37
°C for 4 hours. At the end of the incubation, the fluorescence intensity was monitored in
the same manner as for the measurement in section “Fluorescence imaging”. To calculate
the bacterial number, the same bacterial suspension was used. 100 µL from each dilution
was spread on agar plates without antibiotics and incubated at 37 °C overnight. The
colonies were counted from each plate, and colony numbers were used to calculate
colony forming units (CFU) per mL in the original bacterial suspension.
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4.2.7. Singlet oxygen (1O2) generation
Singlet oxygen generated from p-NBMB solution was monitored by oxidation of
p-nitrosodimethylaniline (RNO).1 It is known that RNO is bleached in the presence of
singlet oxygen, implying that the change in the intensity of RNO absorbance indicates
1

O2 generation.1 A solution of p-NBMB (10 µM) was prepared with the enzyme assay

buffer containing 2 unit mL-1 of NTR and 1 mM of NAD(P)H. The buffer solution
without the redox enzyme was used as a negative control. After incubation of all prepared
samples for various time intervals ranging from 3 h to 24 h at 37 °C, RNO (13.2 µM) and
histidine (21 mM) were added to the solutions. Those solutions were irradiated with a HeNe laser (632 nm, 110 mW/cm2, Hughes Research Laboratories, Culver City, CA).
Various irradiation times ranging from 10 to 75 min were used to determine the effect of
irradiation time on 1O2. The optical density at 440 nm (λmax of RNO) was monitored
using a UV-visible spectrophotometer.

4.3. RESULT AND DISCUSSION
The caged NIR fluorescent probe p-NBMB was synthesized in straightforward
steps using MB and p-nitrobenzyl as shown in Scheme 4.2.. Initially, MB in toluene
(80% v/v in water) was reduced to obtain the activated leuco form of MB (leuco-MB).
The yellow toluene phase containing leuco-MB was transferred into 4-nitrobenzyl
chloroformate in toluene to afford the caged p-NBMB. The orange solid resultant pNBMB was characterized by elemental analysis and 1H-NMR spectroscopy. The proton
NMR of p-NBMB in CDCl3 in Fig. 4.1. showed all the characteristic peaks and splitting,
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which indicated successful p-NBMB synthesis. The chemical shift value of the two
protons after the reaction was deshielded from 4.82 ppm to 5.32 ppm, which is indicative
of the formation of the carbamate bond.

Scheme 4.2. Synthetic schemes of fluorescent probe p-NBMB. Reagents and
conditions: (i) methylene blue, Sodium dithionate, Sodium bicarbonate, H2O/Toluene,
50 °C, 1 h; (ii) Leuco Methylene blue, 4-nitrobenzyl chloroformate, dry toluene,(1) 0
°C, (2) Overnight.
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Figure 4.1. 1H NMR spectrum of p-NBMB in CDCl3.

The spectral analysis of p-NBMB was compared with that of a fluorophore MB as
a reference. In spectroscopic evaluation of MB and p-NBMB, MB exhibits maximal
absorbance at 665 nm and fluorescence at 685 nm (λex = 665 nm) (Fig. 4.2). In contrast,
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p-NBMB displayed neither significant absorbance nor fluorescence excitation at 665 nm.
This phenomenon appears to be caused by the interruption of π-conjugation system
bridging the three rings of MB, which quenches the absorbance between 500 nm to 800
nm. This result indicated that p-NBMB exhibits no fluorescence when the signal
compound MB is caged with the nitrobenzyl moiety redox switch as illustrated in
Scheme 4.1, which should lead to diminished noise in clinical imaging applications.

Figure 4.2. Absorbance spectra of imaging probe p-NBMB (dashed line) and MB
(solid line) as a reference by UV spectroscopy.

105

Figure 4. 3. Change in fluorescence intensity of p-NBMB (10 µM) after 3, 6, 9, 12, and
24 hours of incubation with NTR (1 unit mL-1)/NAD(P)H (1 mM). The negative control
did not include the enzyme and NAD(P)H. Spectra were acquired in 10 mM PBS, pH 7.4
with the excitation at 580 nm.
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Figure 4.4. Heterogeneity of p-NBMB in addition of NTR (1 unit) with NAD(P)H (1
mM). Thin ﬁlm ﬂuorescence emission spectra were obtained at 541 nm excitation.
The selective uncaging via nitro reduction was assessed using NfsA, which is the
major NTR from E. coli. As expected, p-NBMB exhibited a selective response for NTR,
shown in Figure 4.3. The fluorescence spectrum of the control revealed no emission
between 640 and 800 nm when excited by either 580 nm light using a fluorescence
spectrometer or by 514.5 nm laser light, unless NTR is added in the solution.
Heterogeneities of reduced p-NBMB were further observed with thin film fluorescence
emission spectra as shown in Fig. 4.4. After reduction of p-NBMB by NTR, several
different peaks were recovered in addition to the dominant 680 nm peak in the spectrum
(Fig. 4.4.). These results might be due to the formation of aggregates and excimers when
the reduced p-NBMB interacts with the surface of a glass cover slip. A previous reported
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study also showed that the fluorophore MB forms dimers in dilute aqueous solutions and
aggregates at increasing concentration due to the strong π-interactions among MB
molecules.112 Thus, peaks from dimer and aggregates would appear on the longer
wavelength at 712 nm and 728 nm due to the transition dipole moment from the ground
state to the lower excited state, called the N-branch.113 Considering the increase in
fluorescence intensity in the presence of NTR, we anticipate that uncaging p-NBMB is
dependent on nitroreductase-mediated two-electron reduction of the nitrobenzyl moiety
redox switch.
To verify whether there is a fluorescence response to other redox enzymes, which
catalyze two-electron reduction, p-NBMB emission was investigated using DTdiaphorase. As shown in Fig. 4.5., DT-diaphorase did not induce any noticeable
fluorescence signal enhancement from p-NBMB compared to the negative control
without the enzyme, over an incubation period up to 48 h. According to previous studies
on triggerable fluorescent probes, nitrobenzimidazoles containing aryl nitro groups could
be an efficient redox switch that can be turned on by DT-diaphorase.114 In addition,
CB1954, the aforementioned prodrug carrying aryl nitro groups, was found to be
activated by both DT-diaphorase and NTR but NTR catalyzed the reduction of CB1954
60 times faster than DT-diaphorase.35,
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However, caged p-NBMB with the p-

nitrobenzyl modification on the phenothiazine ring was not activated by DT-diaphorase.
The result indicated that p-NBMB can be selectively reduced in the presence of NTR and
hence can be used for NTR detection.
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Figure 4.5. Fluorescence intensity of p-NBMB (10 µM) treated with redox enzymes.
Negative control did not include enzymes and NAD(P)H
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Figure 4.6. Fluorescence spectra of p-NBMB (1 µM, 10 µM, 100 µM) with NTR (1 unit)
in the presence of NAD(P)H (1 mM) and the negative control without NTR. Spectra were
acquired in 10 mM PBS, pH 7.4 with the excitation at 580 nm.

We also examined changes in fluorescence intensity as a function of
concentration of p-NBMB, following incubation with one unit per mL of NTR. An
increase in fluorescence intensity was observed when the concentration of p-NBMB was
increased from 1 to 10 to 100 µM (Fig. 4.6.). This result indicates that fluorescence
enhancement is dependent on reduction of a p-nitrobenzyl redox switch by NTR.
However, based on qualitative interpretation, the fluorescence intensity was not
proportional to the concentration of p-NBMB within the concentration range. From this
result, we inferred that the fluorescence enhancement would be more related to the
amount of NTR. Hence, two concentrations of NTR, 1 unit mL-1 and 2 units mL-1, were
tested to observe the redox enzyme capacity in releasing fluorophore MB from p-NBMB
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Figure 4.7. Fluorescence intensity from p-NBMB at a concentration of 1 µM, 10 µM
and 100 µM. The samples were incubated at 37 °C overnight in PBS buffer (pH 7.4)
containing NTR (1 unit mL-1 and 2 units mL-1)
(Fig. 4.7.). At the lowest p-NBMB concentration, 1 µM, the higher fluorescence emission
intensity was similar, regardless of NTR concentrations. This implies that p-NBMB
might show a detection limit at p-NBMB concentrations higher than 1 µM. For better
visualization, we investigated the imaging capacity of p-NBMB using an in vivo imaging
system, a Xenogen IVIS® Spectrum. As expected from the result showing NTR
dependent fluorescence release in Fig. 4.8., images obtained from IVIS® are consistent.
When the fluorescence intensity was compared by the released radiance efficiency in
vivo, there were no statistically significant differences between the two p-NBMB
concentrations. These results suggest that fluorescence emission occurring by p-NBMB
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reduction was predominantly dependent on the reduction capacity of NTR in the presence
of NAD(P)H, providing its potential use for monitoring NTR.

Figure 4.8. Fluorescence response of p-NBMB to nitroreductase. (a) IVIS fluorescence
images of p-NBMB (10 µM, 100 µM) with nitroreductase (1 and 2 unit mL-1, 1 mM
NAD(P)H) and the control without nitroreductase. (b) Quantitation of fluorescence from
each group. Data shown as mean ± SD (n = 3). Spectra were acquired after incubation at
37 °C overnight in 10 mM PBS (pH 7.4).

Since we are interested in p-NBMB application not only in NTR activatable
imaging in vitro but also for therapeutic purposes, we primarily focused on the
characterization of the NTR selectivity of p-NBMB. This can be eventually translated
into therapeutic advances in photodynamic therapy using fluorophores. Hence, we further
examined the fluorescence response of p-NBMB to intact E. coli K12 strain XL1-Blue.
When incubated with 109 CFU mL-1 of E. coli, the NIR fluorescent probe p-NBMB was
112

activated and released a fluorophore showing emission as indicated in the images in Fig.
4.9 (A). In addition, p-NBMB demonstrated a concentration dependent increase in
fluorescence intensity in the presence of bacteria. When the p-NBMB concentration is 1
µM as this bacterial concentration, no noticeable change in fluorescence emission was
observed, indicating that the detection limit is 1 µM. This result is consistent with Fig.
4.7. We also used a serial dilution of a bacterial suspension to determine in vitro
sensitivity of p-NBMB fluorescence to bacterial number. As shown in Fig. 4.9., the raw
fluorescence images and the quantified data indicated that fluorescence intensity from pNBMB is correlated with an increase in bacterial number. At the concentration and
incubation time shown, the detection limit ranged between 107 and 108 CFU mL-1.
However, optimizing concentration of p-NBMB and incubation time could likely
increase this limit. These observations implied that E. coli expressing NTR activates
reduction of a redox switch in p-NBMB to facilitate release of a fluorophore, MB.
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Figure 4.9. (A) IVIS fluorescence images of p-NBMB (1 - 50 µM) incubated with intact E.
coli K12 strain XL1-Blue (109 CFU mL-1) at 37 °C for 4 hours. (B) Sensitivity of p-NBMB
fluorescence to bacterial number. IVIS fluorescence images of p-NBMB (50 µM)
incubated with a serial dilution of the intact E. coli K12 strain XL1-Blue suspension at 37
°C for 4 hours.
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Figure 4.10. Singlet oxygen (1O2) generation from p-NBMB solution (A) with or (B)
without NTR/NAD(P)H was monitored using p-nitrosodimethylaniline (RNO) upon laser
light irradiation at a wavelength of 632 nm. Various irradiation times ranging from 10 to
75 min were used to determine the effect of irradiation time on singlet oxygen
production. The concentration of p-NBMB was 10 µM in the enzyme assay buffer
containing NTR at a concentration of 2 units mL-1 and NAD(P)H at a concentration of 1
mM. The intensity of RNO absorbance decreased in the p-NBMB solution containing
NTR/NAD(P)H while the solution without the redox enzyme did not affect RNO
absorbance.

Along with the capacity of p-NBMB for imaging anaerobic bacteria expressing
NTR, p-NBMB might be useful for the detection of hypoxia in application for tumor
diagnosis based on the recently reported studies demonstrating that molecular probes
caged with nitrobenzyl group showed fluorescence enhancement in hypoxia condition
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(1% pO2).116 Moreover, since the fluorophore methylene blue is an effective
photosensitizer for photodynamic therapy, the generation of singlet oxygen (1O2) from pNBMB was tested using p-nitrosodimethylaniline (RNO) before and after activation by
NTR. It is known that RNO is bleached in the presence of single oxygen, implying that
the change in RNO absorbance intensity indicates the generation of 1O2.16 Figure 4.10.(A)
shows that the p-NBMB incubated with NTR/NAD(P)H exhibited a decrease in RNO
absorbance after laser irradiation at a wavelength of 634 nm (110 mW/cm2, Hughes
Research Laboratories, Culver City, CA). In contrast, no significant change in RNO
absorbance was observed from the control after laser exposure (Fig. 4.10.(B)). This result
indicated that free MB released from p-NBMB reduction was able to generate 1O2 upon
an irradiation in a NIR range. Based on the work done by Komine et al. demonstrating
that 1O2 generated from MB (0.01%) with a laser irradiation for 5 min killed E. faecalis
(>99.9%)117, p-NBMB will be beneficial both for targeted diagnostic and therapeutic
applications.

4.4. CONCLUSIONS
We have developed a new NIR fluorescent probe p-NBMB equipped with a pnitrobenzyl redox switch that enables selective switching on of fluorescence by NTR.
Whereas p-NBMB shows no fluorescence emission in PBS buffer at pH 7.4, it exhibits
remarkable NIR fluorescence intensity after undergoing selective reduction by NTR.
Furthermore, p-NBMB fluorescence was induced by incubation with live E. coli bacteria,
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indicating that endogenous NTR can activate the nitrobenzyl moiety switch to generate
the fluorophore. This collectively indicates that p-NBMB would be a suitable imaging
sensor to detect bacteria expressing NTR. In addition, p-NBMB also possesses potential
as an MB prodrug which can be applied for the treatment of various diseases.
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CHAPTER 5
CONCLUSIONS
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Incorporation of redox-responsive functionality, which are a QPA trigger and a
nitrobenzyl trigger, into polymer and fluorophore, respectively, yield the materials with a
redox-responsive property. We have accomplished to obtain the novel redox-responsive
polymeric nanoparticles and micelles using a QPA redox trigger for targeted drug
delivery. We also achieved the synthesis of the new NTR activatable NIR fluorescent
probe caged by nitrobenzyl redox trigger for its selective imaging and therapy. In this
chapter, we summarize dissertation research work consisting of those two materials
prepared from redox triggers and discuss their challenges and future research directions.
Redox-responsive polymer was synthesized with a QPA trigger and utilized for
the preparation of redox-responsive NPs. These NPs enabled to release incorporated drug
triggered by stimulated redox-state using sodium dithionite. These NPs, however, were
noticeably aggregated in aqueous environment because of hydrophobic nature of the
polymer. Since PEG grafting has been established as a vital alternative to overcome
various in vitro/in vivo stability issues of NPs, we adopted this approach to yield redoxresponsive amphiphilic copolymer to improve the polymeric NPs. After successful
mPEG grafting to the redox-sensitive hydrophobic polymer, polyQPA-mPEG became to
be water soluble as well as self-assembled as micelles. In vitro PTX release kinetics has
shown that PTX-loaded redox-responsive polyQPA-mPEG micelles were stable in
aqueous environments and able to release the loaded PTX by redox-triggered QPA
reduction which disrupted micelle structure. During the study on reducing enzyme119

mediated lactone release from redox-responsive micelles, we found that hydrophilic PEG
blocks might contribute to increasing water solubility of polyQPA, thereby facilitating
the binding between the enzyme and QPA triggers on the polymer. Therefore, the
relationships between the structures of the QPA based polymer/monomer and its
reduction activity as substrates of DT-diaphorase are needed to be explored for the
optimization. The modification of polymers for further application in targeted delivery
might be more easily achieved afterward.
We also successfully synthesized a nitroreductase-triggered near infrared
fluorescent probe. Conjugating methylene blue with a redox trigger enables the
fluorescent probe to be activated by 1,6-elimination in the presence of nitroreductase,
resulting in the release of methylene blue fluorophore. We also found that MB release
after the reduction of a probe could produce singlet oxygen, indicating that its potential
use as a therapeutic tool. In the future, kinetics of photoxygeneration of this probe needs
to be evaluated. The photosensitizing efficacy of this probe on viruses, yeasts, and
protozoa also can be conducted for a its wide variety of applications.

120

BIBLIOGRAPHY

121

1.

Fleige, E.; Quadir, M. A.; Haag, R., Stimuli-responsive polymeric nanocarriers

for the controlled transport of active compounds: Concepts and applications. Adv. Drug.
Delivery. Rev. 2012, 64 (9), 866-884.
2.

(a) Garripelli, V. K.; Namgung, R.; Kim, W. J.; Jo, S., Drug Release from a pH-

Sensitive Multiblock Co-Polymer Thermogel. J. Biomater. Sci. Polym. Ed. 2011; (b)
Kim, J. K.; Garripelli, V. K.; Jeong, U. H.; Park, J. S.; Repka, M. A.; Jo, S., Novel pHsensitive polyacetal-based block copolymers for controlled drug delivery. Int. J. Pharm.
2010, 401 (1-2), 79-86.
3.

McCarley, R. L., Redox-responsive delivery systems. Annu. Rev. anal. Chem.

2012, 5, 391-411.
4.

Ku, T.-H.; Chien, M.-P.; Thompson, M. P.; Sinkovits, R. S.; Olson, N. H.; Baker,

T. S.; Gianneschi, N. C., Controlling and switching the morphology of micellar
nanoparticles with enzymes. J. Am. Chem. Soc. 2011, 133 (22), 8392-8395.
5.

Grüll, H., Hyperthermia-triggered drug delivery from temperature-sensitive

liposomes using MRI-guided high intensity focused ultrasound. J. controlled release
2012, 161 (2), 317-327.
6.

Hilderbrand, S. A.; Weissleder, R., Near-infrared fluorescence: application to in

vivo molecular imaging. Current opinion in chemical biology 2010, 14 (1), 71-79.
7.

(a) Benaron, D., The Future of Cancer Imaging. Cancer and Metastasis Reviews

2002, 21 (1), 45-78; (b) Willmann, J. K.; van Bruggen, N.; Dinkelborg, L. M.; Gambhir,
S. S., Molecular imaging in drug development. Nat Rev Drug Discov 2008, 7 (7), 591607.
122

8.

Schaeffter, T., Imaging modalities: principles and information content. In Imaging

in Drug Discovery and Early Clinical Trials, Birkhäuser Basel: 2005; Vol. 62, pp 15-81.
9.

(a) Filonov, G. S.; Piatkevich, K. D.; Ting, L. M.; Zhang, J.; Kim, K.; Verkhusha,

V. V., Bright and stable near-infrared fluorescent protein for in vivo imaging. Nat.
Biotechnol. 2011, 29 (8), 757-61; (b) Schaeffter, T., Imaging modalities: principles and
information content. Prog. Drug Res. 2005, 62, 15-81.
10.

Luo, S.; Zhang, E.; Su, Y.; Cheng, T.; Shi, C., A review of NIR dyes in cancer

targeting and imaging. Biomaterials 2011, 32 (29), 7127-7138.
11.

Johnsson, N.; Johnsson, K., Chemical Tools for Biomolecular Imaging. ACS

Chemical Biology 2007, 2 (1), 31-38.
12.

Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M. T.; Mazur, M.; Telser, J., Free

radicals and antioxidants in normal physiological functions and human disease. Int. J
.Biochem. Cell Biol. 2007, 39 (1), 44-84.
13.

Trachootham, D.; Lu, W.; Ogasawara, M. A.; Nilsa, R. D.; Huang, P., Redox

regulation of cell survival. Antioxid. Redox. Signal. 2008, 10 (8), 1343-74.
14.

Son, S.; Namgung, R.; Kim, J.; Singha, K.; Kim, W. J., Bioreducible Polymers for

Gene Silencing and Delivery. Acc. Chem. Res. 2011, 45 (7), 1100-1112.
15.

Cytarska, J.; Skowerski, K.; Jaworski, S.; Misiura, K.; Filip-Psurska, B.;

Wietrzyk, J., The Disulfide Analogues of Isophosphoramide Mustard for Anticancer
Therapy. Letters in Drug Design & Discovery 2015, 12 (3), 172-179.

123

16.

Cheng, R.; Feng, F.; Meng, F.; Deng, C.; Feijen, J.; Zhong, Z., Glutathione-

responsive nano-vehicles as a promising platform for targeted intracellular drug and gene
delivery. Journal of Controlled Release 2011, 152 (1), 2-12.
17.

(a) Morales, M. C.; Perez-Yarza, G.; Nieto-Rementeria, N.; Boyano, M. D.; Jangi,

M.; Atencia, R.; Asumendi, A., Intracellular glutathione levels determine cell sensitivity
to apoptosis induced by the antineoplasic agent N-(4-hydroxyphenyl) retinamide.
Anticancer Res. 2005, 25 (3B), 1945-51; (b) Allalunis-Turner, M. J.; Lee, F. Y.;
Siemann, D. W., Comparison of glutathione levels in rodent and human tumor cells
grown in vitro and in vivo. Cancer research 1988, 48 (13), 3657-3660.
18.

Senter, P. D., Development of a drug-release strategy based on the reductive

fragmentation of benzyl carbamate disulfides. J. Org. Chem. 1990, 55 (9), 2975-2978.
19.

Kurtoglu, Y. E.; Navath, R. S.; Wang, B.; Kannan, S.; Romero, R.; Kannan, R.

M., Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular
drug delivery. Biomaterials 2009, 30 (11), 2112-21.
20.

Kirpotin, D.; Hong, K.; Mullah, N.; Papahadjopoulos, D.; Zalipsky, S.,

Liposomes

with

detachable

polymer

coating:

destabilization

and

fusion

of

dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly
(ethylene glycol). FEBS letters 1996, 388 (2), 115-118.
21.

Kim, S. H., VEGF siRNA Delivery System Using Arginine-Grafted Bioreducible

Poly(disulfide amine). Mol. Pharm. 2009, 6 (3), 718-726.

124

22.

Williams, S. R.; Lepene, B. S.; Thatcher, C. D.; Long, T. E., Synthesis and

Characterization of Poly(ethylene glycol)−Glutathione Conjugate Self-Assembled
Nanoparticles for Antioxidant Delivery. Biomacromolecules 2009, 10 (1), 155-161.
23.

Ryu, J.-H.; Roy, R.; Ventura, J.; Thayumanavan, S., Redox-Sensitive

Disassembly of Amphiphilic Copolymer Based Micelles. Langmuir 2010, 26 (10), 70867092.
24.

Chen, J.; Qiu, X.; Ouyang, J.; Kong, J.; Zhong, W.; Xing, M. M., pH and

reduction dual-sensitive copolymeric micelles for intracellular doxorubicin delivery.
Biomacromolecules 2011, 12 (10), 3601-3611.
25.

Zhang, Z.; Yin, L.; Tu, C.; Song, Z.; Zhang, Y.; Xu, Y.; Tong, R.; Zhou, Q.; Ren,

J.; Cheng, J., Redox-Responsive, Core Cross-Linked Polyester Micelles. ACS Macro.
Lett. 2012, 2, 40-44.
26.

Vasiliou, V.; Ross, D.; Nebert, D. W., Update of the NAD (P) H: quinone

oxidoreductase (NQO) gene family. Human genomics 2006, 2 (5), 329.
27.

Danson, S.; Ward, T. H.; Butler, J.; Ranson, M., DT-diaphorase: a target for new

anticancer drugs. Cancer treatment reviews 2004, 30 (5), 437-449.
28.

Danson, S.; Ward, T. H.; Butler, J.; Ranson, M., DT-diaphorase: a target for new

anticancer drugs. Cancer Treat Rev 30 (5), 437-449.
29.

(a) Ross, D.; Beall, H.; Traver, R. D.; Siegel, D.; Phillips, R. M.; Gibson, N. W.,

Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical
studies. Oncology research 1993, 6 (10-11), 493-500; (b) Williams, J.; Lu, A.; Cameron,
R.; Pickett, C., Rat liver NAD (P) H: quinone reductase. Construction of a quinone
125

reductase cDNA clone and regulation of quinone reductase mRNA by 3methylcholanthrene and in persistent hepatocyte nodules induced by chemical
carcinogens. Journal of Biological Chemistry 1986, 261 (12), 5524-5528; (c) Workman,
P., Enzyme-directed bioreductive drug development revisited: a commentary on recent
progress and future prospects with emphasis on quinone anticancer agents and quinone
metabolizing enzymes, particularly DT-diaphorase. Oncology research 1993, 6 (10-11),
461-475.
30.

Silvers, W. C.; Payne, A. S.; McCarley, R. L., Shedding light by cancer redox—

human NAD (P) H: quinone oxidoreductase 1 activation of a cloaked fluorescent dye.
Chem. Commun. 2011, 47 (40), 11264-11266.
31.

Hettiarachchi, S. U.; Prasai, B.; McCarley, R. L., Detection and cellular imaging

of human cancer enzyme using a turn-on, wavelength-shiftable, self-immolative
profluorophore. Journal of the American Chemical Society 2014, 136 (21), 7575-7578.
32.

Liu, P.; Xu, J.; Yan, D.; Zhang, P.; Zeng, F.; Li, B.; Wu, S., A DT-diaphorase

responsive theranostic prodrug for diagnosis, drug release monitoring and therapy.
Chemical Communications 2015, 51 (46), 9567-9570.
33.

Volpato, M.; Abou-Zeid, N.; Tanner, R. W.; Glassbrook, L. T.; Taylor, J.;

Stratford, I.; Loadman, P. M.; Jaffar, M.; Phillips, R. M., Chemical synthesis and
biological evaluation of a NAD (P) H: quinone oxidoreductase-1–targeted tripartite
quinone drug delivery system. Molecular cancer therapeutics 2007, 6 (12), 3122-3130.

126

34.

Ong, W.; Yang, Y.; Cruciano, A. C.; McCarley, R. L., Redox-triggered contents

release from liposomes. Journal of the American Chemical Society 2008, 130 (44),
14739-14744.
35.

Knox, R. J.; Friedlos, F.; Sherwood, R. F.; Melton, R. G.; Anlezark, G. M., The

bioactivation of 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954)—II: A comparison of
an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem. pharm. 1992, 44
(12), 2297-2301.
36.

(a) Knox, R. J.; Friedlos, F.; Biggs, P. J.; Flitter, W. D.; Gaskell, M.; Goddard, P.;

Davies, L.; Jarman, M., Identification, synthesis and properties of 5-(aziridin-1-yl)-2nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954.
Biochemical pharmacology 1993, 46 (5), 797-803; (b) Helsby, N. A.; Wheeler, S. J.;
Pruijn, F. B.; Palmer, B. D.; Yang, S.; Denny, W. A.; Wilson, W. R., Effect of
nitroreduction on the alkylating reactivity and cytotoxicity of the 2, 4-dinitrobenzamide5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct
mechanisms of bioreductive activation. Chemical research in toxicology 2003, 16 (4),
469-478; (c) Helsby, N.; Ferry, D.; Patterson, A.; Pullen, S.; Wilson, W., 2-Amino
metabolites are key mediators of CB 1954 and SN 23862 bystander effects in
nitroreductase GDEPT. British journal of cancer 2004, 90 (5), 1084-1092.
37.

Dachs, G. U.; Tupper, J.; Tozer, G. M., From bench to bedside for gene-directed

enzyme prodrug therapy of cancer. Anti-cancer drugs 2005, 16 (4), 349-359.
38.

Jameson, M. B.; Rischin, D.; Pegram, M.; Gutheil, J.; Patterson, A. V.; Denny,

W. A.; Wilson, W. R., A phase I trial of PR-104, a nitrogen mustard prodrug activated by
127

both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer
chemotherapy and pharmacology 2010, 65 (4), 791-801.
39.

Singleton, D.; Li, D.; Bai, S.; Syddall, S.; Smaill, J.; Shen, Y.; Denny, W.;

Wilson, W.; Patterson, A., The nitroreductase prodrug SN 28343 enhances the potency of
systemically administered armed oncolytic adenovirus ONYX-411NTR. Cancer gene
therapy 2007, 14 (12), 953-967.
40.

Hu, L.; Yu, C.; Jiang, Y.; Han, J.; Li, Z.; Browne, P.; Race, P. R.; Knox, R. J.;

Searle, P. F.; Hyde, E. I., Nitroaryl phosphoramides as novel prodrugs for E. coli
nitroreductase activation in enzyme prodrug therapy. Journal of medicinal chemistry
2003, 46 (23), 4818-4821.
41.

Hu, L.; Wu, X.; Han, J.; Chen, L.; Vass, S. O.; Browne, P.; Hall, B. S.; Bot, C.;

Gobalakrishnapillai, V.; Searle, P. F., Synthesis and structure–activity relationships of
nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs. Bioorganic &
medicinal chemistry letters 2011, 21 (13), 3986-3991.
42.

Yang, Y.; Voak, A.; Wilkinson, S. R.; Hu, L., Design, synthesis, and evaluation

of potential prodrugs of DFMO for reductive activation. Bioorganic & Medicinal
Chemistry Letters 2012, 22 (21), 6583-6586.
43.

Sharma, K.; Sengupta, K.; Chakrapani, H., Nitroreductase-activated nitric oxide

(NO) prodrugs. Bioorganic & Medicinal Chemistry Letters 2013, 23 (21), 5964-5967.
44.

Cui, L.; Zhong, Y.; Zhu, W.; Xu, Y.; Du, Q.; Wang, X.; Qian, X.; Xiao, Y., A

new prodrug-derived ratiometric fluorescent probe for hypoxia: high selectivity of
nitroreductase and imaging in tumor cell. Organic letters 2011, 13 (5), 928-931.
128

45.

Shi, Y.; Zhang, S.; Zhang, X., A novel near-infrared fluorescent probe for

selectively sensing nitroreductase (NTR) in an aqueous medium. Analyst 2013, 138 (7),
1952-1955.
46.

(a) Center, M. M.; Jemal, A.; Lortet-Tieulent, J.; Ward, E.; Ferlay, J.; Brawley,

O.; Bray, F., International variation in prostate cancer incidence and mortality rates. Eur.
Urol. 2012, 61 (6), 1079-1092; (b) Garcia, K.; Crimmins, E. M., Cancer Screening in the
US and Europe: Policies, Practices, and Trends in Cancer Incidence and Mortality. In
Applied Demography and Public Health, Springer: 2013; pp 125-154.
47.

Melancon, M. P.; Stafford, R. J.; Li, C., Challenges to effective cancer

nanotheranostics. J. Control Release 2012, 164 (2), 177-82.
48.

Sailor, M. J.; Park, J.-H., Hybrid Nanoparticles for Detection and Treatment of

Cancer. Adv. Mater. 2012, 24 (28), 3779-3802.
49.

Smitskamp-Wilms, E.; Giaccone, G.; Pinedo, H.; van der Laan, B.; Peters, G.,

DT-diaphorase activity in normal and neoplastic human tissues; an indicator for
sensitivity to bioreductive agents? Br. J. cancer 1995, 72 (4), 917.
50.

Ross, D.; Siegel, D.; Beall, H.; Prakash, A.; Mulcahy, R. T.; Gibson, N. W., DT-

diaphorase in activation and detoxification of quinones. Cancer Metastasis Rev. 1993, 12
(2), 83-101.
51.

(a) Siegel, D.; Franklin, W. A.; Ross, D., Immunohistochemical detection of

NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clinical cancer
research : an official journal of the American Association for Cancer Research 1998, 4
(9), 2065-70; (b) Jamieson, D.; Wilson, K.; Pridgeon, S.; Margetts, J. P.; Edmondson, R.
129

J.; Leung, H. Y.; Knox, R.; Boddy, A. V., NAD(P)H:quinone oxidoreductase 1 and
nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and
lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 singlenucleotide polymorphism. Clin. Cancer Res. 2007, 13 (5), 1584-90.
52.

(a) Ong, W.; Yang, Y.; Cruciano, A. C.; McCarley, R. L., Redox-triggered

contents release from liposomes. J. Am. Chem. Soc.
2008, 130 (44), 14739-14744; (b) Silvers, W. C.; Prasai, B.; Burk, D. H.; Brown, M. L.;
McCarley, R. L., Profluorogenic Reductase Substrate for Rapid, Selective, and Sensitive
Visualization and Detection of Human Cancer Cells that Overexpress NQO1. J. Am.
Chem. Soc. 2012, 135 (1), 309-314.
53.

Volpato, M.; Abou-Zeid, N.; Tanner, R. W.; Glassbrook, L. T.; Taylor, J.;

Stratford, I.; Loadman, P. M.; Jaffar, M.; Phillips, R. M., Chemical synthesis and
biological evaluation of a NAD(P)H:quinone oxidoreductase-1–targeted tripartite
quinone drug delivery system. Mol. Cancer Ther. 2007, 6 (12), 3122-3130.
54.

Maskell, L.; Blanche, E. A.; Colucci, M. A.; Whatmore, J. L.; Moody, C. J.,

Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles.
Bioorg. Med. Chem. Lett. 2007, 17 (6), 1575-1578.
55.

Viswanadhan, V. N.; Ghose, A. K.; Revankar, G. R.; Robins, R. K., Atomic

physicochemical parameters for three dimensional structure directed quantitative
structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive
interactions and their application for an automated superposition of certain naturally
occurring nucleoside antibiotics. J. Chem. Inform. Comput. Sci. 1989, 29 (3), 163-172.
130

56.

Klopman, G.; Li, J.-Y.; Wang, S.; Dimayuga, M., Computer Automated log P

Calculations Based on an Extended Group Contribution Approach. J. Chem. Inform.
Comput. Sci. 1994, 34 (4), 752-781.
57.

Cho, H.; Bae, J.; Garripelli, V. K.; Anderson, J. M.; Jun, H.-W.; Jo, S., Redox-

sensitive polymeric nanoparticles for drug delivery. Chem. Commun. 2012, 48 (48),
6043-6045.
58.

Si-Shen, F.; Li, M.; Win, K. Y.; Guofeng, H., Nanoparticles of biodegradable

polymers for clinical administration of paclitaxel. Curr. Med. Chem. 2004, 11 (4), 413424.
59.

Wang, Y.; Yu, L.; Han, L.; Sha, X.; Fang, X., Difunctional Pluronic copolymer

micelles for paclitaxel delivery: Synergistic effect of folate-mediated targeting and
Pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int. J. Pharm.
2007, 337 (1-2), 63-73.
60.

Blakeney, B. A.; Tambralli, A.; Anderson, J. M.; Andukuri, A.; Lim, D. J.; Dean,

D. R.; Jun, H. W., Cell infiltration and growth in a low density, uncompressed threedimensional electrospun nanofibrous scaffold. Biomaterials 2011, 32 (6), 1583-90.
61.

Li, J.; Mahdi, F.; Du, L.; Datta, S.; Nagle, D. G.; Zhou, Y.-D., Mitochondrial

Respiration Inhibitors Suppress Protein Translation and Hypoxic Signaling via the
Hyperphosphorylation and Inactivation of Translation Initiation Factor eIF2α and
Elongation Factor eEF2. J J. Nat. Prod. 2011, 74 (9), 1894-1901.
62.

Rubinstein, L. V.; Shoemaker, R. H.; Paull, K. D.; Simon, R. M.; Tosini, S.;

Skehan, P.; Scudiero, D. A.; Monks, A.; Boyd, M. R., Comparison of In Vitro
131

Anticancer-Drug-Screening Data Generated With a Tetrazolium Assay Versus a Protein
Assay Against a Diverse Panel of Human Tumor Cell Lines. J. Natl. Cancer Inst. 1990,
82 (13), 1113-1117.
63.

Costache, A. D.; Sheihet, L.; Zaveri, K.; Knight, D. D.; Kohn, J., Polymer−Drug

Interactions in Tyrosine-Derived Triblock Copolymer Nanospheres: A Computational
Modeling Approach. Mol. Pharm. 2009, 6 (5), 1620-1627.
64.

Gaumet, M.; Vargas, A.; Gurny, R.; Delie, F., Nanoparticles for drug delivery: the

need for precision in reporting particle size parameters. Eur. J. Pharm. Biopharm. 2008,
69 (1), 1-9.
65.

Chernysheva, Y. V., Effect of the type of hydrophobic polymers on the size of

nanoparticles obtained by emulsification–solvent evaporation. Mendeleev commun. 2003,
13 (2), 65-67.
66.

Song, K. C.; Lee, H. S.; Choung, I. Y.; Cho, K. I.; Ahn, Y.; Choi, E. J., The effect

of type of organic phase solvents on the particle size of poly (D, L-lactide-co-glycolide)
nanoparticles. Colloids Surf. A Physicochem Eng. Asp. 2006, 276 (1), 162-167.
67.

Sameti, M.; Bohr, G.; Ravi Kumar, M. N. V.; Kneuer, C.; Bakowsky, U.; Nacken,

M.; Schmidt, H.; Lehr, C. M., Stabilisation by freeze-drying of cationically modified
silica nanoparticles for gene delivery. Int. J. Pharm. 2003, 266 (1–2), 51-60.
68.

Abdelwahed, W.; Degobert, G.; Stainmesse, S.; Fessi, H., Freeze-drying of

nanoparticles: formulation, process and storage considerations. Adv. Drug. Delivery. Rev.
2006, 58 (15), 1688-1713.

132

69.

Abdelwahed, W.; Degobert, G.; Fessi, H., A pilot study of freeze drying of

poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): Formulation
and process optimization. Int. J. Pharm. 2006, 309 (1–2), 178-188.
70.

Cavatur, R.; Vemuri, N. M.; Pyne, A.; Chrzan, Z.; Toledo-Velasquez, D.;

Suryanarayanan, R., Crystallization Behavior of Mannitol in Frozen Aqueous Solutions.
Pharm. Res. 2002, 19 (6), 894-900.
71.

Yu, L.; Milton, N.; Groleau, E. G.; Mishra, D. S.; Vansickle, R. E., Existence of a

mannitol hydrate during freeze-‐drying and practical implications. J. Pharm. Sci. 1999, 88
(2), 196-198.
72.

Abdelwahed, W.; Degobert, G.; Stainmesse, S.; Fessi, H., Freeze-drying of

nanoparticles: formulation, process and storage considerations. Adv. Drug Deliv. Rev.
2006, 58 (15), 1688-713.
73.

Mayhew, S. G., The Redox Potential of Dithionite and SO−2 from Equilibrium

Reactions with Flavodoxins, Methyl Viologen and Hydrogen plus Hydrogenase. Eur. J.
Biochem. 1978, 85 (2), 535-547.
74.

Lim, Y.-B.; Han, S.-O.; Kong, H.-U.; Lee, Y.; Park, J.-S.; Jeong, B.; Kim, S. W.,

Biodegradable polyester, poly [α-(4-aminobutyl)-L-glycolic acid], as a non-toxic gene
carrier. Pharm. Res. 2000, 17 (7), 811-816.
75.

Price, P. J.; Gregory, E. A., Relationship between in vitro growth promotion and

biophysical and biochemical properties of the serum supplement. In vitro 1982, 18 (6),
576-584.

133

76.

Allen, T. M.; Cullis, P. R., Drug delivery systems: entering the mainstream.

Science 2004, 303 (5665), 1818-1822.
77.

Danhier, F.; Feron, O.; Préat, V., To exploit the tumor microenvironment: passive

and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control
Release 2010, 148 (2), 135-146.
78.

Maeda, H., The enhanced permeability and retention (EPR) effect in tumor

vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme
Regul 2001, 41 (1), 189-207.
79.

Garripelli, V. K.; Kim, J.-K.; Namgung, R.; Kim, W. J.; Repka, M. A.; Jo, S., A

novel thermosensitive polymer with pH-dependent degradation for drug delivery. Acta
biomater 2010, 6 (2), 477.
80.

Kim, J.-K.; Anderson, J.; Jun, H.-W.; Repka, M. A.; Jo, S., Self-assembling

peptide amphiphile-based nanofiber gel for bioresponsive cisplatin delivery. Mol
Pharmaceutics 2009, 6 (3), 978-985.
81.

Grüll, H.; Langereis, S., Hyperthermia-triggered drug delivery from temperature-

sensitive liposomes using MRI-guided high intensity focused ultrasound. J Control
Release 2012, 161 (2), 317-327.
82.

Cho, H.; Bae, J.; Garripelli, V. K.; Anderson, J. M.; Jun, H.-W.; Jo, S., Redox-

sensitive polymeric nanoparticles for drug delivery. Chem Commun 2012, 48 (48), 60436045.

134

83.

Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M. T. D.; Mazur, M.; Telser, J., Free

radicals and antioxidants in normal physiological functions and human disease. Int J
Biochem Cell Biol 2007, 39 (1), 44-84.
84.

Phillips, D. J.; Gibson, M. I., Redox-Sensitive Materials for Drug Delivery:

Targeting the Correct Intracellular Environment, Tuning Release Rates, and Appropriate
Predictive Systems. Antioxid Redox Signal 2014, 21 (5), 786-803.
85.

(a) Saito, G.; Swanson, J. A.; Lee, K.-D., Drug delivery strategy utilizing

conjugation via reversible disulfide linkages: role and site of cellular reducing activities.
Adv Drug Delivery Rev 2003, 55 (2), 199-215; (b) Huo, M.; Yuan, J.; Tao, L.; Wei, Y.,
Redox-responsive polymers for drug delivery: from molecular design to applications.
Polym Chem 2014, 5 (5), 1519-1528; (c) Cho, Y. W.; Lee, J.; Lee, S. C.; Huh, K. M.;
Park, K., Hydrotropic agents for study of in vitro paclitaxel release from polymeric
micelles. J Control Release 2004, 97 (2), 249-257.
86.

Volpato, M.; Abou-Zeid, N.; Tanner, R. W.; Glassbrook, L. T.; Taylor, J.;

Stratford, I.; Loadman, P. M.; Jaffar, M.; Phillips, R. M., Chemical synthesis and
biological evaluation of a NAD(P)H:quinone oxidoreductase-1–targeted tripartite
quinone drug delivery system. Mol Cancer Ther 2007, 6 (12), 3122-3130.
87.

(a) Fuhrhop, J. H.; Hungerbuehler, H.; Siggel, U., Quinone-containing

amphiphiles and bolaform amphiphiles that form redox-active lipid membranes.
Langmuir 1990, 6 (7), 1295-1300; (b) Levine, M. N.; Raines, R. T., Trimethyl lock: a
trigger for molecular release in chemistry, biology, and pharmacology. Chem Sci 2012, 3
(8), 2412-2420.
135

88.

(a)

Schlager,

J.

J.;

Powis,

G.,

Cytosolic

NAD(P)H:(Quinone-

acceptor)oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking
and alcohol. Int J Cancer 1990, 45 (3), 403-409; (b) Bey, E. A.; Bentle, M. S.; Reinicke,
K. E.; Dong, Y.; Yang, C.-R.; Girard, L.; Minna, J. D.; Bornmann, W. G.; Gao, J.;
Boothman, D. A., An NQO1- and PARP-1-mediated cell death pathway induced in nonsmall-cell lung cancer cells by β-lapachone. Proc Natl Acad Sci USA 2007, 104 (28),
11832-11837.
89.

(a) Mendoza, M. F.; Hollabaugh, N. M.; Hettiarachchi, S. U.; McCarley, R. L.,

Human NAD(P)H:Quinone Oxidoreductase Type I (hNQO1) Activation of Quinone
Propionic Acid Trigger Groups. Biochemistry 2012, 51 (40), 8014-8026; (b)
Pitchuanchom, S.; Songsiang, U.; Weerapreeyakul, N.; Yenjai, C., Anticancer activity of
the bioreductive and non-bioreductive zerumbone derivatives. Letters in Drug Design &
Discovery 2011, 8 (6), 536-543.
90.

Bae, J.; Nael, M. A.; Jiang, L.; Hwang, P. T.; Mahdi, F.; Jun, H.-W.; Elshamy, W.

M.; Zhou, Y.-D.; Murthy, S. N.; Doerksen, R. J.; Jo, S., Quinone propionic acid-based
redox-triggered polymer nanoparticles for drug delivery: Computational analysis and in
vitro evaluation. J Appl Polym Sci 2014, 131 (13), 40461.
91.

Yoo, J.-W.; Chambers, E.; Mitragotri, S., Factors that control the circulation time

of nanoparticles in blood: challenges, solutions and future prospects. Curr Pharm Des
2010, 16 (21), 2298-2307.
92.

(a) Brigger, I.; Dubernet, C.; Couvreur, P., Nanoparticles in cancer therapy and

diagnosis. Advanced drug delivery reviews 2002, 54 (5), 631-651; (b) Moghimi, S. M.;
136

Hunter, A. C.; Murray, J. C., Long-circulating and target-specific nanoparticles: theory to
practice. Pharmacological reviews 2001, 53 (2), 283-318; (c) Davis, S., Biomedical
applications of nanotechnology—implications for drug targeting and gene therapy.
Trends in biotechnology 1997, 15 (6), 217-224.
93.

Kim, S. C.; Kim, D. W.; Shim, Y. H.; Bang, J. S.; Oh, H. S.; Kim, S. W.; Seo, M.

H., In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.
Journal of Controlled Release 2001, 72 (1–3), 191-202.
94.

(a) Kim, J. K.; Garripelli, V. K.; Jeong, U. H.; Park, J. S.; Repka, M. A.; Jo, S.,

Novel pH-sensitive polyacetal-based block copolymers for controlled drug delivery. Int J
Pharm 2010, 401 (1-2), 79-86; (b) Ahn, J. S.; Suh, J. M.; Lee, M.; Jeong, B., Slow
eroding biodegradable multiblock poloxamer copolymers. Polymer international 2005,
54 (5), 842-847.
95.

Wang, Y.; Yu, L.; Han, L.; Sha, X.; Fang, X., Difunctional Pluronic copolymer

micelles for paclitaxel delivery: Synergistic effect of folate-mediated targeting and
Pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int J Pharm
2007, 337 (1-2), 63-73.
96.

(a) Carpino, L. A.; Triolo, S. A.; Berglund, R. A., Reductive lactonization of

strategically methylated quinone propionic acid esters and amides. J Org Chem 1989, 54
(14), 3303-3310; (b) Ong, W.; McCarley, R. L., Redox-driven shaving of dendrimers.
Chem Commun 2005, (37), 4699-4701.
97.

Alexandridis, P.; Holzwarth, J. F.; Hatton, T. A., Micellization of poly (ethylene

oxide)-poly (propylene oxide)-poly (ethylene oxide) triblock copolymers in aqueous
137

solutions: thermodynamics of copolymer association. Macromolecules 1994, 27 (9),
2414-2425.
98.

Croy, S. R.; Kwon, G. S., The effects of Pluronic block copolymers on the

aggregation state of nystatin. J Control Release 2004, 95 (2), 161-171.
99.

Huh, K. M.; Min, H. S.; Lee, S. C.; Lee, H. J.; Kim, S.; Park, K., A new

hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel. J
Control Release 2008, 126 (2), 122-129.
100.

Kim, S. Y.; Shin, I. L. G.; Lee, Y. M.; Cho, C. S.; Sung, Y. K., Methoxy

poly(ethylene glycol) and ϵ-caprolactone amphiphilic block copolymeric micelle
containing indomethacin.: II. Micelle formation and drug release behaviours. J Control
Release 1998, 51 (1), 13-22.
101.

Sezgin, Z.; Yüksel, N.; Baykara, T., Preparation and characterization of polymeric

micelles for solubilization of poorly soluble anticancer drugs. Eur J Pharm Biopharm
2006, 64 (3), 261-268.
102.

Ulbrich, K.; Koňák, Č.; Tuzar, Z.; Kopeček, J., Solution properties of drug

carriers based on poly [N-(2-hydroxypropyl) methacrylamide] containing biodegradable
bonds. Die Makromolekulare Chemie 1987, 188 (6), 1261-1272.
103.

Yoo, H. S.; Park, T. G., Biodegradable polymeric micelles composed of

doxorubicin conjugated PLGA–PEG block copolymer. Journal of Controlled Release
2001, 70 (1–2), 63-70.
104.

(a) Xiong, J.; Meng, F.; Wang, C.; Cheng, R.; Liu, Z.; Zhong, Z., Folate-

conjugated crosslinked biodegradable micelles for receptor-mediated delivery of
138

paclitaxel. Journal of Materials Chemistry 2011, 21 (15), 5786-5794; (b) Ruoslahti, E.;
Bhatia, S. N.; Sailor, M. J., Targeting of drugs and nanoparticles to tumors. The Journal
of cell biology 2010, 188 (6), 759-768.
105.

Palmer, B. D.; van Zijl, P.; Denny, W. A.; Wilson, W. R., Reductive chemistry of

the novel hypoxia-selective cytotoxin 5-[N, N-bis (2-chloroethyl) amino]-2, 4dinitrobenzamide. Journal of medicinal chemistry 1995, 38 (7), 1229-1241.
106.

(a) Searle, P. F.; Chen, M. J.; Hu, L.; Race, P. R.; Lovering, A. L.; Grove, J. I.;

Guise, C.; Jaberipour, M.; James, N. D.; Mautner, V., Nitroreductase: a prodrug-‐
activating enzyme for cancer gene therapy. Clin. Exp. Pharmacol. Physiol. 2004, 31 (11),
811-816; (b) Huang, H.-C.; Wang, K.-L.; Huang, S.-T.; Lin, H.-Y.; Lin, C.-M.,
Development of a sensitive long-wavelength fluorogenic probe for nitroreductase: A new
fluorimetric indictor for analyte determination by dehydrogenase-coupled biosensors.
Biosens. Bioelectron. 2011, 26 (8), 3511-3516.
107.

Denny, W. A., Nitroreductase-based GDEPT. Current pharmaceutical design

2002, 8 (15), 1349-1361.
108.

(a) Benaron, D., The Future of Cancer Imaging. Cancer Metast. Rev. 2002, 21 (1),

45-78; (b) Willmann, J. K.; van Bruggen, N.; Dinkelborg, L. M.; Gambhir, S. S.,
Molecular imaging in drug development. Nat. Rev. Drug Discov. 2008, 7 (7), 591-607.
109.

(a) Tanaka, E.; Chen, F. Y.; Flaumenhaft, R.; Graham, G. J.; Laurence, R. G.;

Frangioni, J. V., Real-time assessment of cardiac perfusion, coronary angiography, and
acute intravascular thrombi using dual-channel near-infrared fluorescence imaging. The
Journal of thoracic and cardiovascular surgery 2009, 138 (1), 133-140; (b) Tang, W.;
139

Xu, H.; Kopelman, R.; Philbert, M. A., Photodynamic Characterization and In Vitro
Application of Methylene Blue-‐containing Nanoparticle Platforms¶. Photochemistry and
photobiology 2005, 81 (2), 242-249.
110.

(a) Wendel, W. B., The control of methemoglobinemia with methylene blue.

Journal of Clinical Investigation 1939, 18 (2), 179; (b) Ormeci, N.; Savas, B.; Coban, S.;
Palabıyıkoğlu, M.; Ensari, A.; Kuzu, I.; Kursun, N., The usefulness of chromoendoscopy
with methylene blue in Barrett’s metaplasia and early esophageal carcinoma. Surg.
Endosc. 2008, 22 (3), 693-700.
111.

(a) Wagner, M.; Suarez, E.; Theodoro, T.; Machado Filho, C.; Gama, M.;

Tardivo, J.; Paschoal, F.; Pinhal, M., Methylene blue photodynamic therapy in malignant
melanoma decreases expression of proliferating cell nuclear antigen and heparanases.
Clin. Exp. Derma. 2012, 37 (5), 527-533; (b) Floyd, R. A.; Schneider, J. E.; Dittmer, D.
P., Methylene blue photoinactivation of RNA viruses. Antiviral Res. 2004, 61 (3), 141151; (c) Perdrau, J.; Todd, C., The photodynamic action of methylene blue on certain
viruses. Proceedings of the Royal Society of London. Series B, Containing Papers of a
Biological Character 1933, 288-298; (d) Tardivo, J. P.; Del Giglio, A.; de Oliveira, C. S.;
Gabrielli, D. S.; Junqueira, H. C.; Tada, D. B.; Severino, D.; de Fátima Turchiello, R.;
Baptista, M. S., Methylene blue in photodynamic therapy: from basic mechanisms to
clinical applications. Photodiagnosis and Photodynamic Therapy 2005, 2 (3), 175-191.
112.

(a) Fornili, S. L., Solvent isotope effect in the monomer?dimer equilibrium of

methylene blue. J. Chem. Soc. Faraday Trans. 1981, 77 (12), 3049; (b) Heger, D.,
Aggregation of Methylene Blue in Frozen Aqueous Solutions Studied by Absorption
140

Spectroscopy. J. Phys. Chem. A 2005, 109 (30), 6702-6709; (c) Jockusch, S.; Turro, N.
J.; Tomalia, D. A., Aggregation of Methylene Blue Adsorbed on Starburst Dendrimers.
Macromolecules 1995, 28 (22), 7416-7418.
113.

Patil, K.; Pawar, R.; Talap, P., Self-aggregation of Methylene Blue in aqueous

medium and aqueous solutions of Bu4NBr and urea. Phys. Chem. Chem. Phys. 2000, 2
(19), 4313-4317.
114.

Anusevičius, Ž.; Nivinskas, H.; Segura-Aguilar, J., Nitrobenzimidazoles as

substrates for DT-diaphorase and redox cycling compounds: their enzymatic reactions
and cytotoxicity. Arch. of biochem. biophys. 1997, 346 (2), 219-229.
115.

Anlezark, G. M.; Melton, R. G.; Sherwood, R. F.; Coles, B.; Friedlos, F.; Knox,

R. J., The bioactivation of 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954)—I:
purification and properties of a nitroreductase enzyme from Escherichia coli—a potential
enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. pharm. 1992,
44 (12), 2289-2295.
116.

Kraljic, I.; Mohsni, S. E.; Arvis, M., A GENERAL METHOD FOR THE

IDENTIFICATION

OF

PRIMARY

REACTIONS

IN

SENSITIZED

PHOTOOXIDATIONS*. Photochemistry and Photobiology 1978, 27 (5), 531-537.
117.

Komine, C.; Tsujimoto, Y., A Small Amount of Singlet Oxygen Generated via

Excited Methylene Blue by Photodynamic Therapy Induces the Sterilization of
Enterococcus faecalis. Journal of Endodontics 39 (3), 411-414.

141

VITA

Jungeun Bae was born in Daegu, South Korea on July 12, 1983. She is the
daughter of Taegoon Bae and Hoyeon Kim. She graduated from Kyungbook National
University, Daegu, South Korea where she obtained her Bachelor of Science in Life
Science and Biotechnology in August of 2009. During her tenure there, she taught
freshman level Calculus and Sciences to high school students and educated in minority
mention program. After the completion of her Bachelor degree, she worked in the
Kyungbook National University Biomolecular & Cellular Biology laboratory under Dr.
Young-seuk Bae. In the August of 2010, she joined the research lab of Dr. Seongbong Jo
at the Department of Pharmaceutics and Drug Delivery in the School of Pharmacy at The
University of Mississippi to pursue Doctor of Philosophy in Pharmaceutical Sciences.

HONORS and FELLOWSHIPS
Summer Research Assistantship Awards, University of Mississippi

2015

Dissertation Fellowship Award, University of Mississippi

2015

The Mississippi Biophysical Consortium Annual Meeting Travel award

2013

Initiation of Rho Chi Honors society

2011
142

PUBLICATIONS
J Bae; LE McNamara; MA Nael; RJ Doerksen; GL Bidwell III; NI Hammer; S Jo,
"Nitroreductase-triggered activation of a novel caged fluorescent probe", Chem. Commun., 51,
2015, 12787-12790.
J Bae; A Maurya; S Zia; SN Murthy; S Jo, "Novel redox-responsive amphiphilic copolymer
micelles for drug delivery: Synthesis and characterization", AAPS Journal, 17(6), 2015, 135768.
J Bae; MA Nael; L Jiang, PT Hwang, F Mahdi; HW Jun; WM. Elshamy; YD Zhou; SN
Murthy; RJ Doerksen; S Jo, "Quinone propionic acid-based redox-triggered polymer
nanoparticles for drug delivery: computational analysis and in vitro evaluation", J. Appl. Polym.
Sci., 131, 2014, 40461.
H Cho; J Bae; VK Garripelli; JM Anderson; H-W Jun; S Jo; "Redox-sensitive polymeric
nanoparticles for drug delivery." Chem. Commun., 48, 2012, 6043-6045.

143

